<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2023-00030232</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1648396-01</rr:TRF>
    <rr:MRN>21088846</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1333169" clinicalId="1334516" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1648396-01</ReportId>
      <SampleName>US1572255.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1648396-01</FM_Id>
        <SampleId>US1572255.01</SampleId>
        <BlockId>S112-66324A (PF23077)</BlockId>
        <TRFNumber>ORD-1648396-01</TRFNumber>
        <TestType>FoundationOne CDX</TestType>
        <SpecFormat>Slide Deck</SpecFormat>
        <ReceivedDate>2023-06-09</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1648396-01</ReportId>
        <MRN>21088846</MRN>
        <FullName>Chien, Ching I</FullName>
        <FirstName>Ching I</FirstName>
        <LastName>Chien</LastName>
        <SubmittedDiagnosis>Unspecified primary endometrioid carcinoma</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1971-11-08</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Pelvis</SpecSite>
        <CollDate>2023-03-28</CollDate>
        <ReceivedDate>2023-06-09</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives>
        <PertinentNegative>
          <Gene>BRCA1</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>BRCA2</Gene>
        </PertinentNegative>
      </PertinentNegatives>
      <Summaries alterationCount="34" clinicalTrialCount="37" resistiveCount="0" sensitizingCount="10" />
      <VariantProperties>
        <VariantProperty geneName="ARAF" isVUS="true" variantName="G371V" />
        <VariantProperty geneName="CTCF" isVUS="true" variantName="G261C" />
        <VariantProperty geneName="DIS3" isVUS="true" variantName="A494V" />
        <VariantProperty geneName="EGFR" isVUS="true" variantName="T638M" />
        <VariantProperty geneName="EPHA3" isVUS="true" variantName="G584V" />
        <VariantProperty geneName="FH" isVUS="true" variantName="A42T" />
        <VariantProperty geneName="FLCN" isVUS="true" variantName="S331F" />
        <VariantProperty geneName="GATA3" isVUS="true" variantName="R74M" />
        <VariantProperty geneName="GID4 (C17orf39)" isVUS="true" variantName="P75R" />
        <VariantProperty geneName="GNAQ" isVUS="true" variantName="T54M" />
        <VariantProperty geneName="IGF1R" isVUS="true" variantName="G1328S" />
        <VariantProperty geneName="IKBKE" isVUS="true" variantName="R456Q" />
        <VariantProperty geneName="NOTCH3" isVUS="true" variantName="D1598V" />
        <VariantProperty geneName="NTRK1" isVUS="true" variantName="P351H" />
        <VariantProperty geneName="POLE" isVUS="true" variantName="S1757N" />
        <VariantProperty geneName="RAD51D" isVUS="true" variantName="A52V" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>ARID1A</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>G324fs*39</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="34.08" isEquivocal="false" name="G324fs*39" />
              </AlterationProperties>
              <Interpretation>ARID1A encodes the AT-rich interactive domain-containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan-On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46-50%), ovarian and uterine endometrioid carcinomas (24-44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, 2023) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). Several studies have reported no correlation between ARID1A loss and clinicopathological parameters in ovarian clear cell or endometrioid carcinomas or other endometrial cancers (Rahman et al., 2013; 22939958, Maeda et al., 2010; 21614196, Lowery et al., 2012; 22193641, Fadare et al., 2013; 23524907), whereas others suggest that ARID1A loss is a negative prognostic factor (Mao et al., 2013; 24076775, Katagiri et al., 2012; 22101352). There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib (Williamson et al., 2016; 27958275). In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib (Aggarwal et al., 2021; ESMO Abstract 512O). One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124). In a Phase 1 trial, a patient with metastatic colorectal cancer (CRC) harboring both an ARID1A mutation and ATM loss treated with single-agent M6620 achieved a CR that was ongoing at 29 months (Yap et al., 2020; 32568634). On the basis of limited clinical and preclinical evidence, ARID1A inactivation may predict sensitivity to EZH2 inhibitors (Papadopoulos et al., 2022; ENA Abstract 188, Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009). A Phase 1 study of EZH2 inhibitor CPI-0209 reported 1 PR for a patient with ARID1A-mutated endometrial cancer (Papadopoulos et al., 2022; ENA Abstract 188). Other studies have reported that the loss of ARID1A may activate the PI3K-AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti-PD-1 or anti-PD-L1 immunotherapy (Okamura et al., 2020; 32111729). Loss of ARID1A expression has been associated with chemoresistance to platinum-based therapy for patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5-fluorouracil in CRC cell lines (Xie et al., 2014; 24833095).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT02264678">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04657068">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05252390">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05327010">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04802174">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04104776">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04514497">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05053971">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04840589">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05071937">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>ATM</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>S214fs*40</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="32.75" isEquivocal="false" name="S214fs*40" />
              </AlterationProperties>
              <Interpretation>ATM encodes the protein ataxia telangiectasia mutated, which is a serine/threonine protein kinase that plays a key role in the DNA damage response (Shiloh and Ziv, 2013; 23847781). Loss of functional ATM promotes tumorigenesis (Cremona and Behrens, 2014; 23851492). Alterations such as seen here may disrupt ATM function or expression (Jiang et al., 2006; 16603769, Fernandes et al., 2005; 15713674, Scott et al., 2002; 11805335). ATM mutations have been reported in up to 1.3% of ovarian serous carcinoma samples analyzed (Cancer Genome Atlas Research Network., 2011; 21720365). In another study of patients with peritoneal, Fallopian tube, or ovarian carcinoma, somatic loss-of-function mutations in ATM have been found in 3/367 cases (Pennington et al., 2014; 24240112). The homologous recombination pathway has been reported to be disrupted in over 50% of high-grade serous ovarian cancer cases analyzed, including ATM or ATR mutations in 2% of tumors sampled (Colombo et al., 2013; 24071502, Cancer Genome Atlas Research Network, 2011; 21720365). A lack of ATM protein expression was reported in 11.3% of ovarian serous carcinomas, but this ATM deficiency was not significantly correlated with clinicopathological features (Ye at al., 2014; 24752797). ATM protein expression was found in 46.2% (79/171) of sporadic ovarian carcinomas analyzed in one study; the authors suggest that this may be compensatory expression in homologous recombination deficient cancer cells (Wysham et al., 2012; 22253870). In one study, high expression of ATM protein significantly correlated with poor progression-free survival in ovarian serous cystadenocarcinomas (Abdel-Fatah et al., 2014; 26674120). Loss of functional ATM results in a defective DNA damage response and homologous recombination-mediated DNA repair and may predict sensitivity to PARP inhibitors (Michels et al., 2014; 24037533, Bryant and Helleday, 2006; 16556909). Clinical responses have been reported for patients with ATM-mutated prostate cancer treated with PARP inhibitors (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346) and PARP inhibitors have shown limited clinical benefit for patients with other ATM-mutated solid tumors including pancreatic cancer (Ma et al., 2022; ASCO GI Abstract 563, Dhawan et al., 2020; ASCO Abstract 3513), colorectal cancer (Ma et al., 2022; ASCO GI Abstract 563, Gruber et al., 2019; ASCO Abstract 3006, Papageorgiou et al., 2021; 35004311), papillary renal cell carcinoma (Olson et al., 2016; 27079472), ovarian cancer (Swisher et al., 2021; 33941784), small cell bowel cancer, (Dhawan et al., 2020; ASCO Abstract 3513), and biliary tract cancer (Piha-Paul et al., 2018; AACR-NCI-EORTC Abstract A096, Zhang et al., 2020; 32045060). In Phase 1 trials of ATR inhibitors, a heavily pretreated patient with colorectal cancer who achieved a CR to berzosertib (O'Carrigan et al., 2016; ASCO Abstract 2504) and 4 out of 4 patients with diverse solid tumors who achieved PRs to BAY1895344 (Yap et al., 2020; 32988960) harbored ATM inactivation or protein loss. In a Phase 2 study of a combination of the ATR inhibitor ceralasertib and durvalumab for patients with advanced gastric cancer, objective responses (ORs) were experienced by 50% (4/8) of patients with loss of ATM expression, compared with 14% (3/21) patients with intact ATM (Kwon et al., 2022; 35790315). Studies showing reduced cell viability and increased DNA damage in preclinical models of solid tumors (Menezes et al., 2015; 25232030, Vendetti et al., 2015; 26517239, Min et al., 2017; 28138034) and hematologic malignancies (Menezes et al., 2015; 25232030, Kwok et al., 2016; 26563132) also support the increased sensitivity of ATM-deficient cells to ATR inhibitors. Preclinical experiments also indicate that loss of ATM causes dependency on DNA-PKcs in cancer cells; DNA-PKcs inhibitors promoted apoptosis in ATM-deficient cells and were active in a lymphoma mouse model lacking ATM activity (Riabinska et al., 2013; 23761041). Alterations in DNA repair genes such as BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN, PALB2, RAD51C, and RAD51D have been reported to be predictive for sensitivity to platinum agents and improved OS in Stage 2-4 ovarian, fallopian tube, and peritoneal carcinomas (p=0.0006)(Pennington et al., 2014; 24240112). One or more of the ATM variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with ataxia-telangiectasia syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. ATM mutation carriers have increased cancer risk, with carriers assigned female at birth displaying a 38% lifetime risk of breast cancer (van Os et al., 2016; 26662178). Biallelic mutations in ATM underlie the rare autosomal-recessive inherited disorder ataxia-telangiectasia (A-T), also referred to as genome instability or DNA damage response syndrome (Rothblum-Oviatt et al., 2016; 27884168). This disease is characterized by genomic instability, sensitivity to DNA-damaging agents, and increased risk of developing cancer (Shiloh and Ziv, 2013; 23847781, Rothblum-Oviatt et al., 2016; 27884168). The prevalence of A-T is estimated at 1:40,000 to 1:100,000 worldwide (Rothblum-Oviatt et al., 2016; 27884168). In the appropriate clinical context, germline testing of ATM is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna-Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT05489211">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04434482">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04884360">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04518501">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04517357">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05489926">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03983226">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05652283">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03742895">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02264678">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>MSI-High</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="MSI-High" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample has a high level of MSI, equivalent to the clinical definition of an MSI-high (MSI-H) tumor: one with mutations in &gt;30% of microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI-H status indicates high-level deficiency in MMR and typically correlates with loss of expression of at least one, and often two, MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI-high (MSI-H) has been reported in 1.6-19.7% of ovarian cancer samples (Segev et al., 2015; 26775351, Plisiecka-Hałasa et al., 2008; 18507046), including 3.8% (1/26) of ovarian endometrioid adenocarcinomas (Huang et al., 2015; 25195947), and 10.0% (3/30) of ovarian clear cell carcinomas (CCOCs) (Strickland et al., 2016; ASCO Abstract 5514). No association of MSI-H with stage or survival was found in patients with ovarian cancer (Segev et al., 2015; 26775351, Aysal et al., 2012; 22189970). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD-1-targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD-L1-targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). While approximately 80% of MSI-H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Atezolizumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC) as well as adult and pediatric patients 2 years and older with alveolar soft part sarcoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non-squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600-positive melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data showing efficacy of atezolizumab alone or in combination with antiangiogenic therapy for patients with MSI-H colorectal cancer (Hochster et al., 2017; ASCO Abstract 673) or endometrial cancer (Fleming et al., 2018; ASCO Abstract 5585), MSI-H status may predict sensitivity to atezolizumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A case study described a near-complete radiographic response for a patient with PD-L1-negative MSI-H serous ovarian cancer treated with atezolizumab following progression on bevacizumab and chemotherapy (Ak et al., 2021; 33458824). A Phase 1 study of single-agent atezolizumab for patients with advanced or metastatic epithelial ovarian cancer reported an ORR of 22% (2/9), a median PFS (mPFS) of 2.9 months, and a median OS (mOS) of 11.3 months; both objective responses occurred in PD-L1-positive patients (≥5% of immune cells) (Liu et al., 2019; 31204078). A Phase 1b study for patients with platinum-resistant ovarian cancer reported signals of activity and efficacy with the combination of atezolizumab and bevacizumab (ORR of 15% [3/20], DCR of 55% [11/20], mPFS of 4.9 months, and mOS of 10.2 months) (Moroney et al., 2020; 32723836). In the placebo-controlled Phase 3 IMagyn050 study, the addition of atezolizumab to bevacizumab and chemotherapy (paclitaxel plus carboplatin) did not improve mPFS for patients with newly diagnosed Stage III or IV ovarian cancer in the intention-to-treat population (19.5 vs. 18.4 months, HR=0.92) or in the PD-L1-positive population (20.8 vs. 18.5 months, HR=0.80) (Moore et al., 2021; 33891472). For patients with relapsed platinum-sensitive ovarian cancer, the Phase 3 ATALANTE trial reported the addition of atezolizumab to bevacizumab plus platinum-based chemotherapy did not improve mPFS in the intent-to-treat population (13.5 vs. 11.3 months, HR=0.83) or the PD-L1 positive population (15.2 vs. 13.1 months, HR=0.86), though mOS was numerically longer in the atezolizumab cohort (35.5 vs. 30.6 months, HR=0.81) (Kurtz et al., 2022; ESMO Abstract LBA30). In a Phase 2b study for patients with recurrent platinum-resistant ovarian, Fallopian tube, or primary peritoneal cancer, the addition of acetylsalicylic acid to atezolizumab and bevacizumab did not significantly improve outcomes relative to the addition of placebo (Banerjee et al., 2021; ESMO Abstract LBA32). In the prospective Phase 2a MyPathway basket study evaluating atezolizumab for patients with TMB-High solid tumors, patients with TMB ≥16 Muts/Mb achieved improved ORR (38% [16/42] vs. 2.1% [1/48]), DCR (62% [26/42] vs. 23% [11/48]), mPFS (5.7 vs. 1.8 months, HR 0.34), and mOS (19.8 vs. 11.4, HR 0.53) as compared to those with TMB ≥10 and &lt;16 Muts/Mb (Friedman et al., 2022; 34876409). In a retrospective analysis of patients with 17 solid tumor types (comprised of 47% NSCLC, 40% urothelial carcinoma, and 13% encompassing 15 other solid tumors), TMB of 16 Muts/Mb or greater was reported to be associated with an improved ORR to atezolizumab compared to chemotherapy (30% vs. 14%)(Legrand et al., 2018; ASCO Abstract 12000). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Durvalumab + Tremelimumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Durvalumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses; tremelimumab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)-blocking antibody. These therapies are FDA approved in combination to treat adult patients with unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical data across solid tumors (Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152), microsatellite instability high (MSI-H) status may predict sensitivity to combination durvalumab and tremelimumab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 umbrella study of patients with platinum-resistant ovarian cancer reported 1 CR and 10 PRs across 2 cohorts for the combination treatment with durvalumab and tremelimumab plus chemotherapy, with 2 different doses of tremelimumab (Lee et al., 2022; 35320892). Another Phase 2 study of durvalumab and tremelimumab added to frontline neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer reported an overall ORR of 87% (Park et al., 2022; AACR abstract CT010). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Pembrolizumab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden-high (≥10 Muts/Mb), microsatellite instability-high (MSI-H), or MMR-deficient (dMMR) solid tumors; as monotherapy for PD-L1-positive head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD-L1-positive triple-negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with non-small cell lung cancer (NSCLC), melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, MSI-H or dMMR endometrial carcinoma, classical Hodgkin lymphoma, or primary mediastinal large B-cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, urothelial carcinoma, or endometrial carcinoma that is not MSI-H or dMMR. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of multiple prospective clinical studies showing efficacy of pembrolizumab against MSI-H or mismatch repair-deficient (dMMR) solid tumors (Ayers et al., 2016; ASCO-SITC Abstract P60, Diaz et al., 2016; ASCO Abstract 3003, Fader et al., 2016; SGO Abstract 3, Le et al., 2015; 26028255, Le et al., 2016; ASCO GI Abstract 195, Chao et al., 2020; ASCO GI Abstract 430), MSI-H status may predict sensitivity to pembrolizumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; For patients with ovarian cancer enrolled in various clinical trials, a Tumor Mutational Burden (TMB) of 10 Muts/Mb or higher was associated with an ORR of 17% (n=12) on pembrolizumab, whereas a lower TMB was associated with an ORR of 7% (n=281) (Marcus et al., 2021; 34083238). The Phase 2 KEYNOTE-158 study of pembrolizumab for patients with advanced previously treated microsatellite instability-high or MMR-deficient non-colorectal cancer reported an ORR of 33% (8/24, 3 CRs), median PFS of 2.2 months, and median OS of 33.6 months for patients with ovarian cancer (Maio et al., 2022; 35680043). The Phase 2 KEYNOTE-100 study of pembrolizumab for patients with platinum-resistant ovarian cancer demonstrated that greater PD-L1 expression (combined positive score [CPS] ≥10) correlated with improved response rate, with ORRs and DCRs of 17% and 42% (7 CRs, 7 PRs, 20 SDs) in the CPS ≥10 cohort, 10% and 38% (7 CRs, 13 PRs, 55 SDs) in the CPS ≥1 cohort, and 5.0% and 33% (7 PRs, 39 SDs) in the CPS &lt;1 cohort, respectively; BRCA mutation status and homologous recombination deficiency status were not associated with ORR (Matulonis et al., 2019; 31046082). The Phase 1b KEYNOTE-028 study of pembrolizumab in 26 patients with advanced PD-L1-positive (≥1% on tumor or stroma) ovarian cancer reported an ORR of 12% and a DCR of 39% (1 CR, 2 PRs, 7 SDs), with a median PFS and OS of 1.9 and 13.8 months, respectively (Varga et al., 2019; 30522700). Clinical benefit has been observed from the combination of pembrolizumab with niraparib (Konstantinopoulos et al., 2019; 31194228) or bevacizumab and cyclophosphamide (Zsiros et al., 2019; SGO Abstract LBA4). In the Phase 2 PEACOCC trial for previously treated ovarian clear cell cancer, treatment with pembrolizumab monotherapy resulted in a PFS rate of 44% at 12 weeks, confirmed DCR of 44% (21/48), and ORR of 25% (12/48; 1 CR, 11 PR); 1-year PFS and OS rates were 22% and 55%, respectively (Kristeleit et al., 2022; ESMO Abstract 521MO). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Cemiplimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cemiplimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma, or basal cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of prospective clinical data showing efficacy of anti-PD-1 therapies against various MSI-high (MSI-H) solid tumors (Ayers et al., 2016; ASCO-SITC Abstract P60, Diaz et al., 2016; ASCO Abstract 3003, Le et al., 2016; ASCO GI Abstract 195, Fader et al., 2016; SGO Abstract 3, Le et al., 2015; 26028255, Overman et al., 2017; 28734759, Lipson et al., 2013; 23169436), MSI-H status may predict sensitivity to cemiplimab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical data on the efficacy of cemiplimab for the treatment of ovarian cancer are limited (PubMed, Feb 2023). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc-2020-SITC2020.0428). The Phase 3 EMPOWER-Lung 1 trial for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Dostarlimab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Dostarlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). On the basis of prospective clinical data showing efficacy of dostarlimab against various microsatellite instability-high (MSI-H) solid tumors (Oaknin et al., 2020; 33001143, Subramanian et al., 2020; ESMO Abstract 1399P, Andre et al., 2021; ASCO GI Abstract 9, Gabrail et al., 2019; ASCO Abstract 2560), MSI-H status may predict sensitivity to dostarlimab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In the Phase 1 GARNET trial of dostarlimab as a single agent, 2 patients with mismatch repair-deficient (dMMR) ovarian cancer were treated, resulting in 1 PR and 1 SD (Andre et al., 2021; ASCO GI Abstract 9). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair-deficient (dMMR) endometrial and non-endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single-agent dostarlimab elicited an ORR of 39% (41/106) and an immune-related ORR of 46% (50/110) for patients with non-endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO-9). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nivolumab + Ipilimumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pleural mesothelioma, and esophageal squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of ≥10 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. On the basis of clinical data across solid tumors (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Klein et al., 2021; 33856094, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Klein et al., 2021; 33889439, Noor et al., 2021; DOI: 10.1200/JCO.2021.39.3_suppl.415), microsatellite instability high (MSI-H) status may predict sensitivity to combination nivolumab and ipilimumab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a Phase 2 study, patients with recurrent or persistent ovarian cancer treated with nivolumab combined with ipilimumab experienced significantly improved ORR (31% [16/51] vs. 12% [6/49]) and median PFS (3.9 vs. 2.0 months; HR=0.53) than those treated with nivolumab alone; median OS was numerically higher in the combinational group (28.1 vs. 21.8 months), although this result did not reach statistical significance (Zamarin et al., 2020; 32275468). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Avelumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Avelumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in patients with MSI-H colorectal cancer (Hochster et al., 2017; ASCO Abstract 673), endometrial cancer (Fleming et al., 2018; ASCO Abstract 5585), or gastric/gastroesophageal junction cancer (Bang et al., 2018; ASCO Abstract 92), MSI-H status may predict sensitivity to anti-PD-L1 therapies such as avelumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 1b study of single-agent avelumab reported that patients with recurrent or refractory ovarian, fallopian tube, or peritoneal cancer achieved an ORR of 9.6% (12/125), a DCR of 52% (65/125), a median PFS (mPFS) of 2.6 months, and a median OS of 11.2 months; response did not correlate with tumor PD-L1 expression status (Disis et al., 2019; 30676622). In the JAVELIN Ovarian 200 Phase 3 study, the addition of avelumab to pegylated liposomal doxorubicin (PLD) did not improve mPFS (3.7 vs. 3.5 months, HR=0.78) or OS (15.7 vs. 13.1 months, HR=0.89) for unselected patients with platinum-resistant or refractory ovarian, fallopian tube, or peritoneal cancer compared with PLD alone (Pujade-Lauraine et al., 2021; 34143970). In the Phase 3 JAVELIN Ovarian 100 study, avelumab plus chemotherapy regimens did not improve mPFS (16.8-18.1 months vs. not estimable, HR=1.43 and 1.14) compared with chemotherapy alone for patients with treatment-naive ovarian, fallopian tube, or peritoneal cancer (Monk et al., 2021; 34363762). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Retifanlimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Retifanlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with Merkel cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). On the basis of prospective clinical data showing efficacy of anti-PD-1 therapies against various MSI-high (MSI-H) solid tumors (Berton et al., 2021; SITC Abstract 956, Ayers et al., 2016; ASCO-SITC Abstract P60, Diaz et al., 2016; ASCO Abstract 3003, Le et al., 2016; ASCO GI Abstract 195, Fader et al., 2016; SGO Abstract 3, Le et al., 2015; 26028255, Overman et al., 2017; 28734759, Lipson et al., 2013; 23169436), MSI-H status may predict sensitivity to retifanlimab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical data on the efficacy of retifanlimab for the treatment of ovarian cancer are limited (PubMed, Apr 2023). The efficacy of retifanlimab has been demonstrated in various treatment settings for multiple advanced solid tumors, including Merkel cell carcinoma (Grignani et al., 2021; SITC Abstract 545), anal squamous cell carcinoma (SCC) (Rao et al., 2022; 35816951), microsatellite instability-high or deficient MMR endometrial carcinoma (Berton et al., 2021; SITC Abstract 956), glioblastoma (Bagley et al., 2022; SNO Abstract CTIM-35), soft tissue sarcoma (Rosenbaum et al., 2022; ASCO Abstract 11516), and gastroesophageal adenocarcinoma (Catenacci et al., 2022; 36029651). The Phase 2 POD1UM-201 trial of retifanlimab for patients with chemotherapy-naive advanced Merkel cell carcinoma reported an ORR of 51% (33/65; 11 CRs, 22 PRs), unreached median duration of response, and median PFS (mPFS) of 13.8 months (Grignani et al., 2021; SITC Abstract 545). In the Phase 2 POD1UM-202 study for patients with previously treated advanced squamous carcinoma of the anal canal, retifanlimab elicited an ORR of 14% (13/94; 1 CR, 12 PRs), mPFS of 2.3 months, and median OS of 10.1 months, with responses observed regardless of PD-L1 expression (Rao et al., 2022; 35816951). In the Phase 2 POD1UM-203 trial for multiple tumor types, retifanlimab yielded an ORR of 35% (8/23) and mPFS of 4.4 months for patients with treatment-naive metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS ≥50%), an ORR of 40% (14/35) and mPFS of 3.6 months for patients with unresectable or metastatic melanoma, an ORR of 38% (11/29) and mPFS of 5.7 months for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma with PD-L1 expression (CPS ≥10%), and an ORR of 24% (8/34; 1 CR, 7 PRs) and mPFS of 5.4 months for patients with treatment-naive advanced clear cell renal cell carcinoma (RCC) (Maio et al., 2021; ASCO Abstract 2571). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Durvalumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Durvalumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in patients with MSI-H colorectal cancer (Hochster et al., 2017; ASCO Abstract 673), endometrial cancer (Fleming et al., 2018; ASCO Abstract 5585), or gastric/gastroesophageal junction cancer (Bang et al., 2018; ASCO Abstract 92), MSI-H status may predict sensitivity to anti-PD-L1 therapies such as durvalumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Durvalumab has been primarily studied in combination with other agents in ovarian cancers. In a Phase 2 study of durvalumab and olaparib, patients with ovarian cancer achieved an ORR of 15% and a DCR of 53% (5 PR, 13 SD in 34 patients); responses were seen in both BRCA-mutated and BRCA-wildtype patients (Lee et al., 2018; ESMO Abstract 936PD). A study of durvalumab in combination with chemotherapy in patients with newly diagnosed ovarian cancer reported an ORR of 67% (12/18; 1 CR, 11 PRs) and median PFS of 14.5 months (Westin et al., 2020; AACR Abstract CT188). A study comparing durvalumab to physician’s choice chemotherapy for patients with recurrent ovarian clear cell carcinoma reported no significant differences in ORR (11% vs. 19%) or median PFS (7.4 vs 14.0 weeks) following treatment with durvalumab compared to chemotherapy (Tan et al., 2022; ASCO Abstract 5565). In a Phase 1 study of durvalumab in combination with olaparib and cediranib, patients with ovarian cancer achieved an ORR of 29% (2/7) (Zimmer et al., 2017; ESMO Abstract 390P). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nivolumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of prospective clinical data showing efficacy of nivolumab for patients with MSI-H CRC (Overman et al., 2017; 28734759, Lipson et al., 2013; 23169436), MSI-H status may predict sensitivity to nivolumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 study of nivolumab for patients with platinum-resistant ovarian cancer reported an ORR of 15% (3/20), a DCR of 45% (9/20), a median PFS of 3.5 months, and a median OS of 20.0 months (at study termination); 10% (2/20) of patients experienced durable CRs (Hamanishi et al., 2015; 26351349). Similar nivolumab efficacy was seen in a retrospective study in a similar setting (Normann et al., 2019; 31074244). In another Phase 2 study, patients with recurrent or persistent ovarian cancer treated with nivolumab combined with ipilimumab experienced significantly improved ORR (31% [16/51] vs. 12% [6/49]) and median PFS (3.9 vs. 2 months; HR=0.53) than those treated with nivolumab alone; median OS was numerically higher in the combinational group (28.1 vs. 21.8 months), although this result did not reach statistical significance (Zamarin et al., 2020; 32275468). A Phase 2 study combining nivolumab and bevacizumab for patients with relapsed ovarian cancer reported median PFS rates of 12.1 and 7.7 months and ORRs of 40% (8/20) and 17% (3/18) for patients with platinum-sensitive and platinum-resistant cancer, respectively (Liu et al., 2019; 31600397). A Phase 1 trial of nivolumab included 17 cases with ovarian cancer and observed disease control for 24% (1 PR, 3 SDs) of these patients (Brahmer et al., 2012; 22658128). A retrospective case series of 6 patients who were treated with nivolumab as salvage therapy for germline BRCA1/2-mutated recurrent epithelial ovarian and Fallopian tube cancers reported an ORR of 67%, with 3 CRs, 1 PR, and 2 PDs (Matsuo et al., 2018; 29998185). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04237649">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02628067">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04047862">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05166577">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04152018">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03530397">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05092360">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04215978">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03821935">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04282018">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>PIK3R1</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Y452_N453&gt;H, W597fs*2, E601fs*57</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="32.62" isEquivocal="false" name="Y452_N453&gt;H" />
                <AlterationProperty dnaFraction="28.23" isEquivocal="false" name="W597fs*2" />
                <AlterationProperty dnaFraction="25.85" isEquivocal="false" name="E601fs*57" />
              </AlterationProperties>
              <Interpretation>PIK3R1 encodes the p85-alpha regulatory subunit of phosphatidylinositol 3-kinase (PI3K)(Huang et al., 2008; 18418043). Loss of PIK3R1 has been shown to result in increased PI3K signaling (Taniguchi et al., 2010; 20530665, Luo et al., 2006; 16679293, Ueki et al., 2003; 14504291, Mauvais-Jarvis et al., 2002; 11781359), promote tumorigenesis (Taniguchi et al., 2010; 20530665, Thorpe et al., 2017; 28630349, Li et al., 2019; 30755611), and promote hyperplasia in the context of PTEN-deficiency (Luo et al., 2005; 16006513). Alterations such as seen here may disrupt PIK3R1 function or expression (Jaiswal et al., 2009; 19962665, Cheung et al., 2011; 21984976, Ko et al., 2014; 24651434, Quayle et al., 2012; 23166678, Sun et al., 2010; 20713702, Wu et al., 2009; 19915146, Urick et al., 2011; 21478295, Huang et al., 2007; 18079394, Bousquet et al., 2006; 16917505, Oliver et al., 2017; 28143957, Philp et al., 2001; 11606375, Lucas et al., 2014; 25488983, Chen et al., 2018; 29636477, Cheung et al., 2014; 25284480, Li et al., 2021; 34507989). In the TCGA datasets, PIK3R1 mutation is most frequently observed in endometrial carcinoma (33%)(Cancer Genome Atlas Research Network., 2013; 23636398), glioblastoma (GBM; 11%)(cBio-Brennan et al., 2013; 24120142), uterine carcinosarcoma (11%)(cBioPortal, Jan 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210), and lower grade glioma (5%)(Cancer Genome Atlas Research Network., 2015; 26061751). PIK3R1 is often inactivated by in-frame insertions or deletions (indels), and the majority of this class of mutation (80%) was observed in endometrial carcinoma (Ye et al., 2016; 26657142, Cheung et al., 2011; 21984976, Urick et al., 2011; 21478295), although PIK3R1 indels have been reported in other cancer types such as GBM, cervical squamous cell carcinoma, and urothelial bladder carcinoma (Ye et al., 2016; 26657142). On the basis of limited clinical data, reduced PIK3R1 expression has been associated with reduced disease-free survival in prostate cancer (Munkley et al., 2015; 26501081) and metastasis-free survival in breast cancer (Cizkova et al., 2013; 24229379). PIK3R1 expression is not associated with OS in neuroendocrine tumors (Qian et al., 2013; 23980085). On the basis of clinical (Matulonis et al., 2015; 25528496, Piha-Paul et al., 2015; ASCO Abstract 2516, Pitz et al., 2015; 25605819, Juric et al., 2016; SABCS Abstract P3-14-01) and preclinical (Thorpe et al., 2017; 28630349, Sun et al., 2010; 20713702) data, PIK3R1 alteration may predict sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors. In patients with PIK3R1 mutation and no other alterations in the PI3K-AKT-mTOR pathway, 2 CRs have been achieved by patients with endometrial cancer treated with the pan-PI3K inhibitor pilaralisib (Matulonis et al., 2015; 25528496), and 1 PR has been achieved by a patient with breast cancer treated with the PI3K-alpha inhibitor alpelisib in combination with ribociclib and letrozole (Juric et al., 2016; SABCS Abstract P3-14-01). Limited clinical and preclinical data suggest that PIK3R1 alterations may also be sensitive to inhibitors of mTOR (Groisberg et al., ASCO 2017; Abstract 2582, Basho et al., 2015; European Cancer Congress Abstract 1871, Basho et al., 2017; 27893038, Myers et al., 2016; 27016228, Day et al., 2019; 30420444, Sun et al., 2010; 20713702, Ou et al., 2014; 25193464) or AKT (Groisberg et al., ASCO 2017; Abstract 2582, Li et al., 2019; 30755611, Quayle et al., 2012; 23166678). One preclinical study reported that PIK3R1 truncation mutations in the 299–370 range confer sensitivity to MEK inhibitors (Cheung et al., 2014; 25284480).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04526470">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04817956">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05082025">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04975958">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03586661">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>PTEN</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>R130P, T319fs*1</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="36.94" isEquivocal="false" name="R130P" />
                <AlterationProperty dnaFraction="21.78" isEquivocal="false" name="T319fs*1" />
              </AlterationProperties>
              <Interpretation>PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodríguez-Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andrés-Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). PTEN mutations have been reported in &lt;1% of ovarian serous carcinoma cases (Cancer Genome Atlas Research Network, 2011; 21720365), but may be more common in other subtypes, including endometrioid, with smaller studies identifying mutations 17-34% of cases (Obata et al., 1998; 9605750, Hauke et al., 2019; 30979843, McConechy et al., 2014; 23765252). Loss of heterozygosity at the chromosomal region including PTEN has been reported in 31% (22/72) of epithelial ovarian tumors analyzed, with an incidence of 43% (13/30) in endometrioid tumors and 28% (7/25) in serous tumors and lower incidences in other histological subtypes (Obata et al., 1998; 9605750). Reduced PTEN expression has been reported in 55% (26/47) to 69% (104/151) of ovarian epithelial cancers (Sui et al., 2006; 16525657, Lee and Park, 2009; 19150122). In a study of endometriosis-associated ovarian cancers, loss of PTEN expression has been found in 37% (29/79) of cases (Lai et al., 2013; 23962610). Reduced PTEN expression has been suggested to be associated with poor prognosis in ovarian cancer (Skírnisdóttir and Seidal, 2011; 21792012, Sui et al., 2006; 16525657, Lee and Park, 2009; 19150122). PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). While most clinical studies of PTEN-deficient cancers have not observed efficacy for inhibitors of the PI3K-AKT-mTOR pathway, clinical benefit has been reported in limited studies in prostate cancer (Templeton et al., 2013; 23582881, Sweeney et al., 2021; 34246347, de Bono et al., 2019; 30037818, Saura et al., 2017; 27872130), renal cell carcinoma (RCC) (Voss et al., 2019; 30327302), breast cancer (Andre et al., 2016; 27091708, Dent et al., 2021; 34264439, Schmid et al., 2020; 31841354), and colorectal cancer (CRC) (Gilcrease et al., 2019; 30302599). In the TAPUR study, the mTOR inhibitor temsirolimus met the prespecified threshold of activity for the cohort of solid tumors with PTEN mutations (ORR 7.4%, DCR 26%, n=27) (Wentzel et al., 2023; AACR Abstract CT231). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes-Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha-Paul et al., 2018; AACR Abstract A096). In a Phase 1 study of patients treated with PARP and AKT inhibitors olaparib and capivasertib, two patients with PTEN-mutated ovarian cancer and a patient with PTEN-mutated endometrial cancer achieved clinical benefit (CR, PR, or SD &gt;4 months) (Yap et al, 2020; 32532747). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04434482">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04884360">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04518501">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04517357">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05489926">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03983226">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05652283">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04931342">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02264678">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05170594">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Mutation Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>14</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="14" />
              </AlterationProperties>
              <Interpretation>Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level that may be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). Ovarian carcinomas, including peritoneal and Fallopian tube carcinomas, harbor a median TMB of 2.7-3.6 mutations per megabase (muts/Mb) depending upon subtype, and up to 2.1% of cases have high TMB (&gt;20 muts/Mb)(FMI-Chalmers et al., 2017; 28420421). In a study of high grade serous ovarian cancer, homologous recombination (HR)-deficient tumors, which comprised ~50% of all samples, harbored a higher neoantigen load compared to HR-proficient tumors; higher neoantigen load was associated with longer OS but not disease free survival (Strickland et al., 2016; 26871470). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti-PD-1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan-tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥10 Muts/Mb (as measured by this assay) compared with those with TMB &lt;10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores &lt;10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan-solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and &lt;16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD-1 or PD-L1-targeting agents (Goodman et al., 2017; 28835386).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Atezolizumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC) as well as adult and pediatric patients 2 years and older with alveolar soft part sarcoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non-squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600-positive melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data showing efficacy of atezolizumab alone or in combination with antiangiogenic therapy for patients with MSI-H colorectal cancer (Hochster et al., 2017; ASCO Abstract 673) or endometrial cancer (Fleming et al., 2018; ASCO Abstract 5585), MSI-H status may predict sensitivity to atezolizumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A case study described a near-complete radiographic response for a patient with PD-L1-negative MSI-H serous ovarian cancer treated with atezolizumab following progression on bevacizumab and chemotherapy (Ak et al., 2021; 33458824). A Phase 1 study of single-agent atezolizumab for patients with advanced or metastatic epithelial ovarian cancer reported an ORR of 22% (2/9), a median PFS (mPFS) of 2.9 months, and a median OS (mOS) of 11.3 months; both objective responses occurred in PD-L1-positive patients (≥5% of immune cells) (Liu et al., 2019; 31204078). A Phase 1b study for patients with platinum-resistant ovarian cancer reported signals of activity and efficacy with the combination of atezolizumab and bevacizumab (ORR of 15% [3/20], DCR of 55% [11/20], mPFS of 4.9 months, and mOS of 10.2 months) (Moroney et al., 2020; 32723836). In the placebo-controlled Phase 3 IMagyn050 study, the addition of atezolizumab to bevacizumab and chemotherapy (paclitaxel plus carboplatin) did not improve mPFS for patients with newly diagnosed Stage III or IV ovarian cancer in the intention-to-treat population (19.5 vs. 18.4 months, HR=0.92) or in the PD-L1-positive population (20.8 vs. 18.5 months, HR=0.80) (Moore et al., 2021; 33891472). For patients with relapsed platinum-sensitive ovarian cancer, the Phase 3 ATALANTE trial reported the addition of atezolizumab to bevacizumab plus platinum-based chemotherapy did not improve mPFS in the intent-to-treat population (13.5 vs. 11.3 months, HR=0.83) or the PD-L1 positive population (15.2 vs. 13.1 months, HR=0.86), though mOS was numerically longer in the atezolizumab cohort (35.5 vs. 30.6 months, HR=0.81) (Kurtz et al., 2022; ESMO Abstract LBA30). In a Phase 2b study for patients with recurrent platinum-resistant ovarian, Fallopian tube, or primary peritoneal cancer, the addition of acetylsalicylic acid to atezolizumab and bevacizumab did not significantly improve outcomes relative to the addition of placebo (Banerjee et al., 2021; ESMO Abstract LBA32). In the prospective Phase 2a MyPathway basket study evaluating atezolizumab for patients with TMB-High solid tumors, patients with TMB ≥16 Muts/Mb achieved improved ORR (38% [16/42] vs. 2.1% [1/48]), DCR (62% [26/42] vs. 23% [11/48]), mPFS (5.7 vs. 1.8 months, HR 0.34), and mOS (19.8 vs. 11.4, HR 0.53) as compared to those with TMB ≥10 and &lt;16 Muts/Mb (Friedman et al., 2022; 34876409). In a retrospective analysis of patients with 17 solid tumor types (comprised of 47% NSCLC, 40% urothelial carcinoma, and 13% encompassing 15 other solid tumors), TMB of 16 Muts/Mb or greater was reported to be associated with an improved ORR to atezolizumab compared to chemotherapy (30% vs. 14%)(Legrand et al., 2018; ASCO Abstract 12000). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Pembrolizumab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden-high (≥10 Muts/Mb), microsatellite instability-high (MSI-H), or MMR-deficient (dMMR) solid tumors; as monotherapy for PD-L1-positive head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD-L1-positive triple-negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with non-small cell lung cancer (NSCLC), melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, MSI-H or dMMR endometrial carcinoma, classical Hodgkin lymphoma, or primary mediastinal large B-cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, urothelial carcinoma, or endometrial carcinoma that is not MSI-H or dMMR. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of multiple prospective clinical studies showing efficacy of pembrolizumab against MSI-H or mismatch repair-deficient (dMMR) solid tumors (Ayers et al., 2016; ASCO-SITC Abstract P60, Diaz et al., 2016; ASCO Abstract 3003, Fader et al., 2016; SGO Abstract 3, Le et al., 2015; 26028255, Le et al., 2016; ASCO GI Abstract 195, Chao et al., 2020; ASCO GI Abstract 430), MSI-H status may predict sensitivity to pembrolizumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; For patients with ovarian cancer enrolled in various clinical trials, a Tumor Mutational Burden (TMB) of 10 Muts/Mb or higher was associated with an ORR of 17% (n=12) on pembrolizumab, whereas a lower TMB was associated with an ORR of 7% (n=281) (Marcus et al., 2021; 34083238). The Phase 2 KEYNOTE-158 study of pembrolizumab for patients with advanced previously treated microsatellite instability-high or MMR-deficient non-colorectal cancer reported an ORR of 33% (8/24, 3 CRs), median PFS of 2.2 months, and median OS of 33.6 months for patients with ovarian cancer (Maio et al., 2022; 35680043). The Phase 2 KEYNOTE-100 study of pembrolizumab for patients with platinum-resistant ovarian cancer demonstrated that greater PD-L1 expression (combined positive score [CPS] ≥10) correlated with improved response rate, with ORRs and DCRs of 17% and 42% (7 CRs, 7 PRs, 20 SDs) in the CPS ≥10 cohort, 10% and 38% (7 CRs, 13 PRs, 55 SDs) in the CPS ≥1 cohort, and 5.0% and 33% (7 PRs, 39 SDs) in the CPS &lt;1 cohort, respectively; BRCA mutation status and homologous recombination deficiency status were not associated with ORR (Matulonis et al., 2019; 31046082). The Phase 1b KEYNOTE-028 study of pembrolizumab in 26 patients with advanced PD-L1-positive (≥1% on tumor or stroma) ovarian cancer reported an ORR of 12% and a DCR of 39% (1 CR, 2 PRs, 7 SDs), with a median PFS and OS of 1.9 and 13.8 months, respectively (Varga et al., 2019; 30522700). Clinical benefit has been observed from the combination of pembrolizumab with niraparib (Konstantinopoulos et al., 2019; 31194228) or bevacizumab and cyclophosphamide (Zsiros et al., 2019; SGO Abstract LBA4). In the Phase 2 PEACOCC trial for previously treated ovarian clear cell cancer, treatment with pembrolizumab monotherapy resulted in a PFS rate of 44% at 12 weeks, confirmed DCR of 44% (21/48), and ORR of 25% (12/48; 1 CR, 11 PR); 1-year PFS and OS rates were 22% and 55%, respectively (Kristeleit et al., 2022; ESMO Abstract 521MO). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Cemiplimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cemiplimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma, or basal cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of prospective clinical data showing efficacy of anti-PD-1 therapies against various MSI-high (MSI-H) solid tumors (Ayers et al., 2016; ASCO-SITC Abstract P60, Diaz et al., 2016; ASCO Abstract 3003, Le et al., 2016; ASCO GI Abstract 195, Fader et al., 2016; SGO Abstract 3, Le et al., 2015; 26028255, Overman et al., 2017; 28734759, Lipson et al., 2013; 23169436), MSI-H status may predict sensitivity to cemiplimab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical data on the efficacy of cemiplimab for the treatment of ovarian cancer are limited (PubMed, Feb 2023). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc-2020-SITC2020.0428). The Phase 3 EMPOWER-Lung 1 trial for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Dostarlimab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Dostarlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). On the basis of prospective clinical data showing efficacy of dostarlimab against various microsatellite instability-high (MSI-H) solid tumors (Oaknin et al., 2020; 33001143, Subramanian et al., 2020; ESMO Abstract 1399P, Andre et al., 2021; ASCO GI Abstract 9, Gabrail et al., 2019; ASCO Abstract 2560), MSI-H status may predict sensitivity to dostarlimab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In the Phase 1 GARNET trial of dostarlimab as a single agent, 2 patients with mismatch repair-deficient (dMMR) ovarian cancer were treated, resulting in 1 PR and 1 SD (Andre et al., 2021; ASCO GI Abstract 9). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair-deficient (dMMR) endometrial and non-endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single-agent dostarlimab elicited an ORR of 39% (41/106) and an immune-related ORR of 46% (50/110) for patients with non-endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO-9). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nivolumab + Ipilimumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pleural mesothelioma, and esophageal squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of ≥10 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. On the basis of clinical data across solid tumors (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Klein et al., 2021; 33856094, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Klein et al., 2021; 33889439, Noor et al., 2021; DOI: 10.1200/JCO.2021.39.3_suppl.415), microsatellite instability high (MSI-H) status may predict sensitivity to combination nivolumab and ipilimumab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a Phase 2 study, patients with recurrent or persistent ovarian cancer treated with nivolumab combined with ipilimumab experienced significantly improved ORR (31% [16/51] vs. 12% [6/49]) and median PFS (3.9 vs. 2.0 months; HR=0.53) than those treated with nivolumab alone; median OS was numerically higher in the combinational group (28.1 vs. 21.8 months), although this result did not reach statistical significance (Zamarin et al., 2020; 32275468). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Avelumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Avelumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in patients with MSI-H colorectal cancer (Hochster et al., 2017; ASCO Abstract 673), endometrial cancer (Fleming et al., 2018; ASCO Abstract 5585), or gastric/gastroesophageal junction cancer (Bang et al., 2018; ASCO Abstract 92), MSI-H status may predict sensitivity to anti-PD-L1 therapies such as avelumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 1b study of single-agent avelumab reported that patients with recurrent or refractory ovarian, fallopian tube, or peritoneal cancer achieved an ORR of 9.6% (12/125), a DCR of 52% (65/125), a median PFS (mPFS) of 2.6 months, and a median OS of 11.2 months; response did not correlate with tumor PD-L1 expression status (Disis et al., 2019; 30676622). In the JAVELIN Ovarian 200 Phase 3 study, the addition of avelumab to pegylated liposomal doxorubicin (PLD) did not improve mPFS (3.7 vs. 3.5 months, HR=0.78) or OS (15.7 vs. 13.1 months, HR=0.89) for unselected patients with platinum-resistant or refractory ovarian, fallopian tube, or peritoneal cancer compared with PLD alone (Pujade-Lauraine et al., 2021; 34143970). In the Phase 3 JAVELIN Ovarian 100 study, avelumab plus chemotherapy regimens did not improve mPFS (16.8-18.1 months vs. not estimable, HR=1.43 and 1.14) compared with chemotherapy alone for patients with treatment-naive ovarian, fallopian tube, or peritoneal cancer (Monk et al., 2021; 34363762). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Retifanlimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Retifanlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with Merkel cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). On the basis of prospective clinical data showing efficacy of anti-PD-1 therapies against various MSI-high (MSI-H) solid tumors (Berton et al., 2021; SITC Abstract 956, Ayers et al., 2016; ASCO-SITC Abstract P60, Diaz et al., 2016; ASCO Abstract 3003, Le et al., 2016; ASCO GI Abstract 195, Fader et al., 2016; SGO Abstract 3, Le et al., 2015; 26028255, Overman et al., 2017; 28734759, Lipson et al., 2013; 23169436), MSI-H status may predict sensitivity to retifanlimab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical data on the efficacy of retifanlimab for the treatment of ovarian cancer are limited (PubMed, Apr 2023). The efficacy of retifanlimab has been demonstrated in various treatment settings for multiple advanced solid tumors, including Merkel cell carcinoma (Grignani et al., 2021; SITC Abstract 545), anal squamous cell carcinoma (SCC) (Rao et al., 2022; 35816951), microsatellite instability-high or deficient MMR endometrial carcinoma (Berton et al., 2021; SITC Abstract 956), glioblastoma (Bagley et al., 2022; SNO Abstract CTIM-35), soft tissue sarcoma (Rosenbaum et al., 2022; ASCO Abstract 11516), and gastroesophageal adenocarcinoma (Catenacci et al., 2022; 36029651). The Phase 2 POD1UM-201 trial of retifanlimab for patients with chemotherapy-naive advanced Merkel cell carcinoma reported an ORR of 51% (33/65; 11 CRs, 22 PRs), unreached median duration of response, and median PFS (mPFS) of 13.8 months (Grignani et al., 2021; SITC Abstract 545). In the Phase 2 POD1UM-202 study for patients with previously treated advanced squamous carcinoma of the anal canal, retifanlimab elicited an ORR of 14% (13/94; 1 CR, 12 PRs), mPFS of 2.3 months, and median OS of 10.1 months, with responses observed regardless of PD-L1 expression (Rao et al., 2022; 35816951). In the Phase 2 POD1UM-203 trial for multiple tumor types, retifanlimab yielded an ORR of 35% (8/23) and mPFS of 4.4 months for patients with treatment-naive metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS ≥50%), an ORR of 40% (14/35) and mPFS of 3.6 months for patients with unresectable or metastatic melanoma, an ORR of 38% (11/29) and mPFS of 5.7 months for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma with PD-L1 expression (CPS ≥10%), and an ORR of 24% (8/34; 1 CR, 7 PRs) and mPFS of 5.4 months for patients with treatment-naive advanced clear cell renal cell carcinoma (RCC) (Maio et al., 2021; ASCO Abstract 2571). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Durvalumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Durvalumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in patients with MSI-H colorectal cancer (Hochster et al., 2017; ASCO Abstract 673), endometrial cancer (Fleming et al., 2018; ASCO Abstract 5585), or gastric/gastroesophageal junction cancer (Bang et al., 2018; ASCO Abstract 92), MSI-H status may predict sensitivity to anti-PD-L1 therapies such as durvalumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Durvalumab has been primarily studied in combination with other agents in ovarian cancers. In a Phase 2 study of durvalumab and olaparib, patients with ovarian cancer achieved an ORR of 15% and a DCR of 53% (5 PR, 13 SD in 34 patients); responses were seen in both BRCA-mutated and BRCA-wildtype patients (Lee et al., 2018; ESMO Abstract 936PD). A study of durvalumab in combination with chemotherapy in patients with newly diagnosed ovarian cancer reported an ORR of 67% (12/18; 1 CR, 11 PRs) and median PFS of 14.5 months (Westin et al., 2020; AACR Abstract CT188). A study comparing durvalumab to physician’s choice chemotherapy for patients with recurrent ovarian clear cell carcinoma reported no significant differences in ORR (11% vs. 19%) or median PFS (7.4 vs 14.0 weeks) following treatment with durvalumab compared to chemotherapy (Tan et al., 2022; ASCO Abstract 5565). In a Phase 1 study of durvalumab in combination with olaparib and cediranib, patients with ovarian cancer achieved an ORR of 29% (2/7) (Zimmer et al., 2017; ESMO Abstract 390P). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nivolumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of prospective clinical data showing efficacy of nivolumab for patients with MSI-H CRC (Overman et al., 2017; 28734759, Lipson et al., 2013; 23169436), MSI-H status may predict sensitivity to nivolumab. On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD-1 or PD-L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan-solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 study of nivolumab for patients with platinum-resistant ovarian cancer reported an ORR of 15% (3/20), a DCR of 45% (9/20), a median PFS of 3.5 months, and a median OS of 20.0 months (at study termination); 10% (2/20) of patients experienced durable CRs (Hamanishi et al., 2015; 26351349). Similar nivolumab efficacy was seen in a retrospective study in a similar setting (Normann et al., 2019; 31074244). In another Phase 2 study, patients with recurrent or persistent ovarian cancer treated with nivolumab combined with ipilimumab experienced significantly improved ORR (31% [16/51] vs. 12% [6/49]) and median PFS (3.9 vs. 2 months; HR=0.53) than those treated with nivolumab alone; median OS was numerically higher in the combinational group (28.1 vs. 21.8 months), although this result did not reach statistical significance (Zamarin et al., 2020; 32275468). A Phase 2 study combining nivolumab and bevacizumab for patients with relapsed ovarian cancer reported median PFS rates of 12.1 and 7.7 months and ORRs of 40% (8/20) and 17% (3/18) for patients with platinum-sensitive and platinum-resistant cancer, respectively (Liu et al., 2019; 31600397). A Phase 1 trial of nivolumab included 17 cases with ovarian cancer and observed disease control for 24% (1 PR, 3 SDs) of these patients (Brahmer et al., 2012; 22658128). A retrospective case series of 6 patients who were treated with nivolumab as salvage therapy for germline BRCA1/2-mutated recurrent epithelial ovarian and Fallopian tube cancers reported an ORR of 67%, with 3 CRs, 1 PR, and 2 PDs (Matsuo et al., 2018; 29998185). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04237649">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04589845">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04047862">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05166577">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04152018">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03530397">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05092360">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04215978">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03821935">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04282018">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>CIC</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>L571fs*157, P1248fs*54</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="31.78" isEquivocal="false" name="L571fs*157" />
                <AlterationProperty dnaFraction="30.86" isEquivocal="false" name="P1248fs*54" />
              </AlterationProperties>
              <Interpretation>CIC encodes a transcriptional repressor that plays a role in central nervous system (CNS) development (Lee et al., 2002; 12393275). CIC inactivation has been reported in various malignancies, and is highly recurrent in oligodendroglioma (Bettegowda et al., 2011; 21817013, Yip et al., 2012; 22072542). CIC mutations have been described in various solid tumors, including 1–10% of sequenced gastric, endometrial, and colorectal carcinomas and melanoma tumors (cBioPortal, COSMIC, Jan 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878), although the consequences of CIC mutations in these tumor types have not been studied. CIC mutations have been observed in 58–69% of oligodendrogliomas but are less common in other gliomas, such as astrocytoma or oligoastrocytoma (Bettegowda et al., 2011; 21817013, Yip et al., 2012; 22072542, Sahm et al., 2012; 22588899). Published data investigating the prognostic implications of CIC alterations are generally limited (PubMed, Jun 2023). Conflicting data have been reported regarding the prognostic significance of CIC mutation in oligodendroglioma (Jiao et al., 2012; 22869205, Yip et al., 2012; 22072542, Chan et al., 2014; 24030748). There are no targeted therapies available to address genomic alterations in CIC.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>CTCF</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>A175fs*3</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="30.71" isEquivocal="false" name="A175fs*3" />
              </AlterationProperties>
              <Interpretation>CTCF encodes an 11-zinc-finger protein that is implicated in various regulatory roles, including gene activation and repression, imprinting, insulation, methylation, and X chromosome inactivation (Phillips and Corces, 2009; 19563753). CTCF plays a role in transcriptional regulation of a number of key cancer-associated genes, including the oncogene MYC (Gombert and Krumm, 2009; 19568426) and tumor suppressor TP53 (Soto-Reyes and Recillas-Targa, 2010; 20101205), via maintenance of local DNA methylation status. Decreased expression levels of CTCF and/or BORIS, another 11-zinc-finger transcriptional regulator, were reported to be closely associated with global DNA methylation variability and decreased OS in epithelial ovarian cancer (Woloszynska-Read et al., 2011; 21296871, Kemp et al., 2014; 24794443). Somatic mutations in CTCF are infrequently reported in most cancers, but have been observed more commonly (24%) in uterine corpus endometrial carcinoma (cBioPortal, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210); nearly half of the observed mutations were truncating, suggesting a tumor suppressor role for CTCF in this disease. In addition, CTCF has been found to act as a tumor suppressor in breast cancer cell line studies (Méndez-Catalá et al., 2013; 23908591, Tiffen et al., 2013; 23553099). There are no targeted therapies available to address genomic alterations in CTCF.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>EED</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>I251fs*11</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="39.71" isEquivocal="false" name="I251fs*11" />
              </AlterationProperties>
              <Interpretation>EED encodes a core subunit of the PRC2/EED-EZH2-SUZ12 complex, which methylates histones on DNA to repress transcription and expression of target genes (Kirmizis et al., 2004; 15231737, Kuzmichev et al., 2004; 15099518, Pasini et al., 2004; 15385962, Schlesinger et al., 2007; 17200670, Cao et al., 2014; 24457600). The role of PRC2 in cancer is complex, and the catalytic component EZH2 has been described as both an oncogene and tumor suppressor in different contexts (Xu and Li, 2012; 22475286, Chase and Cross, 2011; 21367748). However, the majority of described EED alterations have loss of function effects (Jain and Di Croce, 2016; 27000413). EED alterations, including frameshift or missense mutations (2%), heterozygous deletions (3-4%), homozygous deletions (10-12%), and concurrent heterozygous deletion and mutation (2-25%), have been frequently observed in malignant peripheral nerve sheath tumors (MPNSTs) (Zhang et al., 2014; 25305755, Conway et al., 2015; 26497635, Lee et al., 2014; 25240281, De Raedt et al., 2014; 25119042). In other tumor types, EED alterations have been reported with the highest incidence in lung adenocarcinoma (6.1%) (Cancer Genome Atlas Research Network., 2014; 25079552), prostate adenocarcinoma (5.1%) (cBio-Kumar et al., 2016; 26928463), endometrial carcinoma (5%) (Cancer Genome Atlas Research Network., 2013; 23636398), bladder carcinoma (4.7%) (Cancer Genome Atlas Research Network., 2014; 24476821), head and neck squamous cell carcinoma (HNSCC) (4.7%) (HNSCC-Cancer Genome Atlas Network., 2015; 25631445), pancreatic intraductal tubulopapillary neoplasm (4.5%, 1/22) (Basturk et al., 2017; 28776573), and myelodysplastic syndrome (MDS) (3.1%) (Ueda et al., 2012; 22733077). Studies have reported no association of EED expression levels with OS for patients with soft tissue sarcoma (Ramaglia et al., 2016; 27471434, Cho et al., 2018; 29415665). In contrast, EED overexpression was associated with aggressive subtypes of B- and T-/natural killer-cell neoplasms, compared with indolent subtypes or normal tissue (Abdalkader et al., 2016; 27311868). There are no therapies available that target EED inactivation. Strategies are being developed to target EED in cancers with excessive PRC2 activation, such as inhibitors that disrupt EED-histone binding (Curtin et al., 2017; 28254486) or prevent PRC2 activation (He et al., 2017; 28135237, Qi et al., 2017; 28135235, Huang et al., 2017; 28092155, Barnash et al., 2017; 28165227, Li et al., 2017; 28072869).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Homologous Recombination status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>HRD Not Detected</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="HRD Not Detected" />
              </AlterationProperties>
              <Interpretation />
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Loss of Heterozygosity score</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>LOH-Low</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="LOH-Low" />
              </AlterationProperties>
              <Interpretation>The loss of heterozygosity (LOH) score is a profile of the percentage of the tumor genome that is under focal loss of one allele (Swisher et al., 2016; 27908594); focal LOH events accumulate as genomic "scars" as a result of incorrect DNA double-strand break repair when the homologous recombination pathway is deficient (HRD) (Abkevich et al., 2012; 23047548, Wang et al., 2012; 22912389, Watkins et al., 2014; 25093514, Vanderstichele et al., 2017; 28950147). HRD and consequent genomic LOH occur as a result of genetic or epigenetic inactivation of one or more of the homologous recombination pathway proteins, including BRCA1, BRCA2, RAD51C, ATM, PALB2, and BRIP1 (Vanderstichele et al., 2017; 28950147, Watkins et al., 2014; 25093514, Cancer Genome Atlas Research Network., 2011; 21720365, Venkitaraman, 2003; 12736286). This sample harbors a genomic LOH score below levels that have been associated with improved rates of clinical benefit from treatment with the PARP inhibitor rucaparib in patients with platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). However, patients with lower genomic LOH have also responded to rucaparib, and this type of LOH score does not preclude benefit from PARP inhibitors (Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In a study of more than 4,000 ovarian, Fallopian tube, or peritoneal cancer samples, genomic LOH score ≥ 16% was identified in 24.2% of BRCA1/2 wild-type cases, deleterious BRCA1/2 mutation was identified in an additional 17.2% of cases, and the remaining 58.7% of cases had LOH score &lt; 16% and were BRCA1/2 wild-type (Elvin et al., 2017; ASCO Abstract 5512). Among the histological subtypes, LOH score ≥ 16% or BRCA1/2 mutation was reported in 42.4% of serous carcinomas, 37.6% of endometrioid carcinomas, 23.5% of carcinosarcomas, 20.6% of neuroendocrine carcinomas, 13.6% of clear cell carcinomas, and 8.1% of mucinous carcinomas; in BRCA1/2 wild-type samples, the median LOH score was significantly higher in serous as compared with non-serous cases (Elvin et al., 2017; ASCO Abstract 5512). In ovarian carcinoma, the median LOH score is significantly higher for BRCA1/2-mutated cases than BRCA1/2 wild-type cases (22.2% vs. 9.8%) (Elvin et al., 2017; ASCO Abstract 5512), and mutation or methylation of BRCA1, BRCA2, or RAD51C has been reported to be enriched in cases with increased genomic LOH (Wang et al., 2012; 22912389, Abkevich et al., 2012; 23047548). One study reported no association between LOH and either tumor stage or grade in ovarian serous carcinoma (Marquard et al., 2015; 26015868). In patients with high-grade serous ovarian carcinoma, the frequency of LOH has been reported to increase significantly with age (Pedersen et al., 2013; 23716468). On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, rucaparib elicited significantly longer median PFS (7.2 vs. 5.0 months, HR=0.51) and improved ORR (33.3% vs. 9.6%, p=0.0003) for patients with LOH score ≥ 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). In the maintenance setting in platinum-sensitive, BRCA1/2 wild-type patients, rucaparib was superior to placebo in both the LOH score ≥ 16% (median PFS, 9.7 vs. 5.4 months; HR=0.44) and LOH score &lt; 16% (median PFS, 6.7 vs. 5.4 months; HR=0.58) cohorts (Coleman et al., 2017; 28916367). Similar results have been reported for maintenance treatment with niraparib in ovarian cancer (Mirza et al., 2016; 27717299) when using a different measure of HRD that includes genomic LOH (Telli et al., 2016; 26957554, Timms et al., 2014; 25475740). Increased LOH has also been associated with improved sensitivity to platinum-containing chemotherapy regimens in patients with ovarian or breast cancer (Wang et al., 2012; 22912389, Telli et al., 2015; 25847929, Isakoff et al., 2015; 25847936).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>MSH6</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>F1088fs*2</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="9.31" isEquivocal="false" name="F1088fs*2" />
              </AlterationProperties>
              <Interpretation>MSH6 encodes MutS homolog 6 protein, a member of the mismatch repair (MMR) gene family. Defective MMR occurring as a result of mutation(s) in the MMR family (MLH1, MSH2, MSH6, or PMS2) can result in microsatellite instability (MSI), common in colon, endometrium, and stomach cancers (You et al., 2010; 21081928). Alterations such as seen here may disrupt MSH6 function or expression (Li et al., 2013; 23622243, Wu et al., 2011; 21720545, Edelbrock et al., 2013; 23391514, Berends et al., 2002; 11709755, Warren et al., 2007; 17531815, Geng et al., 2012; 22277660). In the TCGA ovarian serous cystadenocarcinoma dataset, MSH6 mutations were found in &lt;1.0% of patients, but no MSH6 losses or rearrangements were reported (Cancer Genome Atlas Research Network., 2011; 21720365). The risk of ovarian cancer associated with mutations in MSH6 (approximately 1%) has been reported to be lower than that associated with mutations in MLH1 or MSH2 (12% and 16%, respectively) (Bonadona et al., 2011; 21642682). Numerous studies in various cancer types have shown that MSH6 loss or inactivation is associated with MSI and increased mutation burden (Cancer Genome Atlas Network., 2012; 22810696, You et al., 2010; 21081928, Joly et al., 2015; 25504677, Pritchard et al., 2014; 25255306, Rosty et al., 2014; 25117503, McConechy et al., 2015; 25636458). Clinical studies have shown that MSI is associated with patient responses to anti-programmed death 1 (PD-1) immune checkpoint inhibitors pembrolizumab (Le et al., 2015; ASCO Abstract LBA100)(Le et al., 2015; 26028255) and nivolumab (Lipson et al., 2013; 23169436). Higher mutation burden was also reported to be associated with response to pembrolizumab (Rizvi et al., 2015; 25765070). Furthermore, MSI status correlates with higher PD-1 and PD-L1 expression (Gatalica et al., 2014; 25392179), potential biomarkers of response to PD-1 targeted immunotherapies. Therefore, inactivation of MSH6 may confer sensitivity to anti-PD-1 immune checkpoint inhibitors. One or more of the MSH6 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Lynch syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in MSH6 are associated with both "typical" and "atypical" forms of autosomal dominant Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC), which accounts for 1-7% of all colorectal cancers (Silva et al., 2009; 19466295). Approximately 10% of all Lynch syndrome-associated mutations have been attributed to alterations in MSH6 (Peltomaki, 2005; 16083711). Carriers of mutations in MSH6 have a 60-80% risk of colorectal cancer (Kastrinos and Syngal, 2007; 17920897). Lynch syndrome has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Biallelic germline mutation of MSH6 has been shown to account for 20% of cases of the very rare syndrome Constitutional Mismatch Repair Deficiency (CMMRD), which is characterized by a 95% incidence rate of childhood onset lymphoma, leukemia and brain tumors, followed by early-onset colorectal cancer (reviewed in Wimmer et al., 2008; 18709565, Wimmer et al., 2014; 24737826, Scott et al., 2007; 17259933, Ripperger et al., 2010; 20015892, Baris et al., 2016; 26544533). Given the association between MSH6 and these inherited syndromes, in the appropriate clinical context, germline testing of MSH6 is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>SMARCA4</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>P109fs*194</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="34.42" isEquivocal="false" name="P109fs*194" />
              </AlterationProperties>
              <Interpretation>SMARCA4 encodes the protein BRG1, an ATP-dependent helicase that regulates gene transcription through chromatin remodeling (Wilson and Roberts, 2011; 21654818). SMARCA4 is inactivated in a variety of cancers and considered a tumor suppressor (Shain and Pollack, 2013; 23355908). Alterations such as seen here may disrupt SMARCA4 function or expression (Trotter et al., 2008; 18086889, Shen et al., 2007; 17274598, Dykhuizen et al., 2013; 23698369, Stanton et al., 2016; 27941795, Fernando et al., 2020; 33144586). SMARCA4 mutations have been reported in 1.5% of ovarian serous carcinoma samples analyzed in COSMIC (Oct 2022)(Tate et al., 2019; 30371878). Mutation or loss of SMARCA4 has been shown to be a defining molecular characteristic of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)(Conlon et al., 2016; 26645725, Jelinic et al., 2014; 24658004, Witkowski et al., 2014; 24658002, Ramos et al., 2014; 24658001), similar to malignant rhabdoid tumors (MRT), leading to the suggestion that treatment regimens used for MRT may be applicable for patients with SCCOHT (Jelinic et al., 2014; 24658004). SMARCA4 mutation or loss has been reported in 83-94% of SCCOHT tumors, and both germline and somatic alterations have been reported (Lin et al., 2017; 29102090, Auguste et al., 2020; 32575483, Bailey et al., 2014; 25307865, Jelinic et al., 2014; 24658004, Witkowski et al., 2014; 24658002, Ramos et al., 2014; 24658001). Several studies have shown loss of BRG1 expression due to SMARCA4 gene mutations in SCCOHT samples (Kupryjanczyk et al., 2013; 24375037), compared with other types of ovarian clear cell carcinomas, which generally retain BRG1 expression (Ramos et al., 2014; 24658001, Huang et al., 2013; 24336158). In one study of 3000 primary gynecological tumor samples, loss of SMARCA4 expression was found in 91% (42/46) of primary SCCOHT samples, but only 4% (15/360) of ovarian clear cell carcinomas; concurrent loss of expression of SMARCA4 and SMARCA2 was found to be highly specific for SCCOHT (Karnezis et al., 2015; 26356327). Published data investigating the prognostic implications of SMARCA4 alterations in ovarian carcinoma are limited (PubMed, Aug 2022). There are no therapies available that target genomic alterations in SMARCA4; however, clinical benefit to targeted agents has been observed for patients with certain SMARCA4-deficient tumor types. Based on clinical and preclinical data, patients with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) harboring SMARCA4 loss or inactivation may derive benefit from EZH2 inhibitors such as tazemetostat (Jones et al., 2018; ESMO Abstract 1612PD, Italiano et al., 2018; 29650362, Penebre et al., 2015; EORTC Abstract C87) or CDK4/6 inhibitors such as abemaciclib (Xue et al., 2019; 30718512, Xue et al., 2019; 30718506, Lee et al., 2020; 32704608). For patients with SMARCA4-deficient malignant rhabdoid tumors and thoracic undifferentiated tumors, responses have been observed following treatment with anti-PD-1 (Blay et al., 2021; ASCO Abstract 11520, Takada et al., 2019; 31617320, Zhu et al., 2021; DOI: 10.31487/j.SCR.2021.11.07) or anti-PD-L1 therapies (Utsumi et al., 2022; 3577899, Kunimasa et al., 2021; 34746887, Kawachi et al., 2021; 34030451).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>SOX9</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>V306fs*77</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="36.85" isEquivocal="false" name="V306fs*77" />
              </AlterationProperties>
              <Interpretation>SOX9 encodes a transcription factor important for the development and differentiation of multiple tissues, including cartilage, testis, and prostate (Pritchett et al., 2011; 21237710). SOX9 alterations were reported in 1.31% of solid tumors but not in hematologic malignancies (Zehir et al., 2017; 28481359, Reddy et al., 2017; 28985567, Papaemmanuil et al., 2013; 24030381, Tyner et al., 2018; 30333627, Papaemmanuil et al., 2016; 27276561). Increased expression of SOX9 has been associated with tumor development and/or increased aggressiveness of prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer, glioma, and esophageal adenocarcinoma (Kopp et al., 2012; 23201164, Zhong et al., 2012; 22703285, Wang et al., 2012; 22714060, Clemons et al., 2012; 23064761). There are no therapies available to directly address genomic alterations in SOX9.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ATR, PARP, PD-L1</Target>
          <Locations>Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)</Locations>
          <NCTID>NCT02264678</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ATR</Target>
          <Locations>London (United Kingdom), Girona (Spain), Badalona (Spain), Barcelona (Spain), Zaragoza (Spain), Valencia (Spain), Madrid (Spain), El Palmar (Spain), A Coruña (Spain), Córdoba (Spain)</Locations>
          <NCTID>NCT04657068</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRD4, PARP, AR</Target>
          <Locations>Montana, California, Colorado, Arizona, Michigan, Texas</Locations>
          <NCTID>NCT05252390</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP, BRD4, BRDT, BRD2, BRD3</Target>
          <Locations>Colorado, Illinois, Texas, North Carolina, Georgia</Locations>
          <NCTID>NCT05327010</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ATR</Target>
          <Locations>Maryland</Locations>
          <NCTID>NCT04802174</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>A Study of CPI-0209 in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>EZH2, TOP1</Target>
          <Locations>Washington, Salamanca (Spain), Michigan, Illinois, Ohio, Massachusetts, New Jersey, New York</Locations>
          <NCTID>NCT04104776</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>TOP1, ATR</Target>
          <Locations>California, Arizona, Minnesota, Oklahoma, Missouri, Pennsylvania, Connecticut, New York</Locations>
          <NCTID>NCT04514497</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRD3, BRD4, BRD2, BRDT, HDAC</Target>
          <Locations>Oklahoma, Connecticut, Florida</Locations>
          <NCTID>NCT05053971</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, CTLA-4, BRD4, BRDT, BRD2, BRD3</Target>
          <Locations>Ohio, Pennsylvania, New York, Maryland</Locations>
          <NCTID>NCT04840589</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ARID1A</Gene>
          <Alteration>G324fs*39</Alteration>
          <Title>ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>BRD4, BRDT, BRD2, BRD3, PARP</Target>
          <Locations>Pennsylvania</Locations>
          <NCTID>NCT05071937</NCTID>
          <Note>ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>TROP2, PD-L1, PARP1, PD-1</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Liou Ying Township (Taiwan), Shanghai (China), Seoul (Korea, Republic of), Seodaemun-gu (Korea, Republic of), Suita-shi (Japan), Chuo-ku (Japan), Koto-ku (Japan), Kashiwa (Japan)</Locations>
          <NCTID>NCT05489211</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PARP</Target>
          <Locations>Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Gyeonggi-do (Korea, Republic of), Orange (Australia), Blacktown (Australia), Albury (Australia)</Locations>
          <NCTID>NCT04434482</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>D9319C00001- 1L OC Mono Global RCT</Title>
          <StudyPhase>PHASE 3</StudyPhase>
          <Target>PARP</Target>
          <Locations>Rui'an (China), Wenzhou (China), Jiaxing (China), Shanghai (China), Suzhou (China), Wuxi (China), Nanjing (China), Hefei (China), Guangzhou (China), Urumqi (China)</Locations>
          <NCTID>NCT04884360</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>RARA, PARP</Target>
          <Locations>Zhejiang (China)</Locations>
          <NCTID>NCT04518501</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>RET, SRC, VEGFR2, KIT, PARP</Target>
          <Locations>Hangzhou (China)</Locations>
          <NCTID>NCT04517357</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Hangzhou (China)</Locations>
          <NCTID>NCT05489926</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT03983226</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>FGFR1, CSF1R, VEGFRs, PARP</Target>
          <Locations>Hefei (China)</Locations>
          <NCTID>NCT05652283</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Istanbul (Turkey), Antalya (Turkey), Brasov (Romania)</Locations>
          <NCTID>NCT03742895</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>ATM</Gene>
          <Alteration>S214fs*40</Alteration>
          <Title>Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ATR, PARP, PD-L1</Target>
          <Locations>Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)</Locations>
          <NCTID>NCT02264678</NCTID>
          <Note>Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA-PKcs inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE null</StudyPhase>
          <Target>ADORA2A, CD73, PD-1</Target>
          <Locations>Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri</Locations>
          <NCTID>NCT04237649</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-1</Target>
          <Locations>Taipei (Taiwan), Makati (Philippines), Seoul (Korea, Republic of), North Ryde (Australia), Moscow (Russian Federation), Hod Hasharon (Israel), Drammen (Norway), Glostrup (Denmark), Haar (Germany), Haarlem (Netherlands)</Locations>
          <NCTID>NCT02628067</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, TIGIT</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Hefei (China), Guangdong (China), Changsha (China)</Locations>
          <NCTID>NCT04047862</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>HDAC, PD-1</Target>
          <Locations>Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)</Locations>
          <NCTID>NCT05166577</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, Integrin alpha-V</Target>
          <Locations>Taipei (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Liverpool (Australia), Wollongong (Australia), Bratislava (Slovakia), Washington, California, Arizona, New York</Locations>
          <NCTID>NCT04152018</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-L1, PD-1, CTLA-4</Target>
          <Locations>Taipei (Taiwan), Tainan (Taiwan), Cheongju-si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi-do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)</Locations>
          <NCTID>NCT03530397</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab</Title>
          <StudyPhase>PHASE 3</StudyPhase>
          <Target>IL-2R, PD-1</Target>
          <Locations>Chang Hua (Taiwan), Taichung (Taiwan), Taipei (Taiwan), Daegu (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Singapore (Singapore), South Brisbane (Australia), Adelaide (Australia), East Melbourne (Australia)</Locations>
          <NCTID>NCT05092360</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, OX40</Target>
          <Locations>Changhua (Taiwan), Taipei (Taiwan), Tianan (Taiwan), Hangzhou (China), Shanghai (China), Changsha (China), Wuhan (China), Linyi (China), Gyeonggi-do (Korea, Republic of), Gyeongju (Korea, Republic of)</Locations>
          <NCTID>NCT04215978</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, GARP</Target>
          <Locations>Taichung City (Taiwan), Taipei City (Taiwan), Seoul (Korea, Republic of), Chuo-ku (Japan), Kashiwa-shi (Japan), South Brisbane (Australia), Camperdown (Australia), Ramat Gan (Israel), Tel Aviv-Yafo (Israel), Haifa (Israel)</Locations>
          <NCTID>NCT03821935</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Microsatellite status</Gene>
          <Alteration>MSI-High</Alteration>
          <Title>Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PI3K-delta, PD-1, BTK</Target>
          <Locations>Fuzhou (China), Zhejiang (China), Shanghai (China), Suzhou (China), Changsha (China), Jining (China), Chengdu (China), West Perth (Australia), Adelaide (Australia), Blacktown (Australia)</Locations>
          <NCTID>NCT04282018</NCTID>
          <Note>High microsatellite instability (MSI) may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (alone or in combination with anti-CTLA-4).</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PIK3R1</Gene>
          <Alteration>Y452_N453&gt;H, W597fs*2, E601fs*57</Alteration>
          <Title>Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PI3K-alpha</Target>
          <Locations>Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of)</Locations>
          <NCTID>NCT04526470</NCTID>
          <Note>On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PIK3R1</Gene>
          <Alteration>Y452_N453&gt;H, W597fs*2, E601fs*57</Alteration>
          <Title>Improving Public Cancer Care by Implementing Precision Medicine in Norway</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K-alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL</Target>
          <Locations>Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)</Locations>
          <NCTID>NCT04817956</NCTID>
          <Note>On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PIK3R1</Gene>
          <Alteration>Y452_N453&gt;H, W597fs*2, E601fs*57</Alteration>
          <Title>Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>ER, PI3K</Target>
          <Locations>Texas</Locations>
          <NCTID>NCT05082025</NCTID>
          <Note>On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PIK3R1</Gene>
          <Alteration>Y452_N453&gt;H, W597fs*2, E601fs*57</Alteration>
          <Title>Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PI3K, PD-L1, EP4</Target>
          <Locations>Colorado, Oklahoma, New York, New Jersey, Florida</Locations>
          <NCTID>NCT04975958</NCTID>
          <Note>On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PIK3R1</Gene>
          <Alteration>Y452_N453&gt;H, W597fs*2, E601fs*57</Alteration>
          <Title>Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PI3K, PARP</Target>
          <Locations>Texas</Locations>
          <NCTID>NCT03586661</NCTID>
          <Note>On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PARP</Target>
          <Locations>Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Gyeonggi-do (Korea, Republic of), Orange (Australia), Blacktown (Australia), Albury (Australia)</Locations>
          <NCTID>NCT04434482</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>D9319C00001- 1L OC Mono Global RCT</Title>
          <StudyPhase>PHASE 3</StudyPhase>
          <Target>PARP</Target>
          <Locations>Rui'an (China), Wenzhou (China), Jiaxing (China), Shanghai (China), Suzhou (China), Wuxi (China), Nanjing (China), Hefei (China), Guangzhou (China), Urumqi (China)</Locations>
          <NCTID>NCT04884360</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>RARA, PARP</Target>
          <Locations>Zhejiang (China)</Locations>
          <NCTID>NCT04518501</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>RET, SRC, VEGFR2, KIT, PARP</Target>
          <Locations>Hangzhou (China)</Locations>
          <NCTID>NCT04517357</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Hangzhou (China)</Locations>
          <NCTID>NCT05489926</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT03983226</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>FGFR1, CSF1R, VEGFRs, PARP</Target>
          <Locations>Hefei (China)</Locations>
          <NCTID>NCT05652283</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>AKTs, MEK, ERBB2, PD-L1, VEGFA</Target>
          <Locations>Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Moskva (Russian Federation), Malvern (Australia), Ankara (Turkey), Istanbul (Turkey), Brno (Czechia), Dresden (Germany), Prague (Czechia), Muenchen (Germany)</Locations>
          <NCTID>NCT04931342</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ATR, PARP, PD-L1</Target>
          <Locations>Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)</Locations>
          <NCTID>NCT02264678</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>R130P, T319fs*1</Alteration>
          <Title>A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP, VEGFA</Target>
          <Locations>Tai'an (China)</Locations>
          <NCTID>NCT05170594</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE null</StudyPhase>
          <Target>ADORA2A, CD73, PD-1</Target>
          <Locations>Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri</Locations>
          <NCTID>NCT04237649</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>TRKB, ALK, TRKC, ROS1, TRKA, RET, PD-L1, AKTs, ERBB2, MDM2, PI3K-alpha, RAFs, NRAS</Target>
          <Locations>Taipei City (Taiwan), Taoyuan County (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi'an (China), Tianjin (China), Beijing City (China)</Locations>
          <NCTID>NCT04589845</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, TIGIT</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Hefei (China), Guangdong (China), Changsha (China)</Locations>
          <NCTID>NCT04047862</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>HDAC, PD-1</Target>
          <Locations>Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)</Locations>
          <NCTID>NCT05166577</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, Integrin alpha-V</Target>
          <Locations>Taipei (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Liverpool (Australia), Wollongong (Australia), Bratislava (Slovakia), Washington, California, Arizona, New York</Locations>
          <NCTID>NCT04152018</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-L1, PD-1, CTLA-4</Target>
          <Locations>Taipei (Taiwan), Tainan (Taiwan), Cheongju-si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi-do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)</Locations>
          <NCTID>NCT03530397</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab</Title>
          <StudyPhase>PHASE 3</StudyPhase>
          <Target>IL-2R, PD-1</Target>
          <Locations>Chang Hua (Taiwan), Taichung (Taiwan), Taipei (Taiwan), Daegu (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Singapore (Singapore), South Brisbane (Australia), Adelaide (Australia), East Melbourne (Australia)</Locations>
          <NCTID>NCT05092360</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, OX40</Target>
          <Locations>Changhua (Taiwan), Taipei (Taiwan), Tianan (Taiwan), Hangzhou (China), Shanghai (China), Changsha (China), Wuhan (China), Linyi (China), Gyeonggi-do (Korea, Republic of), Gyeongju (Korea, Republic of)</Locations>
          <NCTID>NCT04215978</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, GARP</Target>
          <Locations>Taichung City (Taiwan), Taipei City (Taiwan), Seoul (Korea, Republic of), Chuo-ku (Japan), Kashiwa-shi (Japan), South Brisbane (Australia), Camperdown (Australia), Ramat Gan (Israel), Tel Aviv-Yafo (Israel), Haifa (Israel)</Locations>
          <NCTID>NCT03821935</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Tumor Mutation Burden</Gene>
          <Alteration>14</Alteration>
          <Title>Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PI3K-delta, PD-1, BTK</Target>
          <Locations>Fuzhou (China), Zhejiang (China), Shanghai (China), Suzhou (China), Changsha (China), Jining (China), Chengdu (China), West Perth (Australia), Adelaide (Australia), Blacktown (Australia)</Locations>
          <NCTID>NCT04282018</NCTID>
          <Note>Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.</Note>
          <Include>true</Include>
        </Trial>
      </Trials>
      <References>
        <Reference number="0">
          <ReferenceId>21900401</ReferenceId>
          <FullCitation>Guan B, et al. Cancer Res. (2011) pmid: 21900401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>22009941</ReferenceId>
          <FullCitation>Jones S, et al. Hum. Mutat. (2012) pmid: 22009941</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>20942669</ReferenceId>
          <FullCitation>Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>20826764</ReferenceId>
          <FullCitation>Jones S, et al. Science (2010) pmid: 20826764</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>24293408</ReferenceId>
          <FullCitation>Yan HB, et al. Carcinogenesis (2014) pmid: 24293408</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>22808142</ReferenceId>
          <FullCitation>Wang DD, et al. PLoS ONE (2012) pmid: 22808142</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>22922871</ReferenceId>
          <FullCitation>Huang J, et al. Nat. Genet. (2012) pmid: 22922871</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>24185513</ReferenceId>
          <FullCitation>Chan-On W, et al. Nat. Genet. (2013) pmid: 24185513</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>21892209</ReferenceId>
          <FullCitation>Mamo A, et al. Oncogene (2012) pmid: 21892209</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>22484628</ReferenceId>
          <FullCitation>Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>22037554</ReferenceId>
          <FullCitation>Wang K, et al. Nat. Genet. (2011) pmid: 22037554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>30371878</ReferenceId>
          <FullCitation>Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>22588877</ReferenceId>
          <FullCitation>Cerami E, et al. Cancer Discov (2012) pmid: 22588877</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>23550210</ReferenceId>
          <FullCitation>Gao J, et al. Sci Signal (2013) pmid: 23550210</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>24618703</ReferenceId>
          <FullCitation>Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>23525077</ReferenceId>
          <FullCitation>Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>23318448</ReferenceId>
          <FullCitation>Streppel MM, et al. Oncogene (2014) pmid: 23318448</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>24293293</ReferenceId>
          <FullCitation>Jiao Y, et al. J. Pathol. (2014) pmid: 24293293</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>24563076</ReferenceId>
          <FullCitation>Ross JS, et al. Oncologist (2014) pmid: 24563076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>25195947</ReferenceId>
          <FullCitation>Huang HN, et al. Histopathology (2015) pmid: 25195947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>25394778</ReferenceId>
          <FullCitation>Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>23702729</ReferenceId>
          <FullCitation>Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>23887303</ReferenceId>
          <FullCitation>Allo G, et al. Mod. Pathol. (2014) pmid: 23887303</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>32111729</ReferenceId>
          <FullCitation>Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>24925223</ReferenceId>
          <FullCitation>Chou A, et al. Hum. Pathol. (2014) pmid: 24925223</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>25311944</ReferenceId>
          <FullCitation>Ye J, et al. Hum. Pathol. (2014) pmid: 25311944</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>25561809</ReferenceId>
          <FullCitation>Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>25583476</ReferenceId>
          <FullCitation>Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>22915242</ReferenceId>
          <FullCitation>Abe H, et al. Virchows Arch. (2012) pmid: 22915242</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>24767857</ReferenceId>
          <FullCitation>Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>22939958</ReferenceId>
          <FullCitation>Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>21614196</ReferenceId>
          <FullCitation>Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>22193641</ReferenceId>
          <FullCitation>Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>23524907</ReferenceId>
          <FullCitation>Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>24076775</ReferenceId>
          <FullCitation>Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>22101352</ReferenceId>
          <FullCitation>Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>27958275</ReferenceId>
          <FullCitation>Williamson CT, et al. Nat Commun (2016) pmid: 27958275</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>29252124</ReferenceId>
          <FullCitation>Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>32568634</ReferenceId>
          <FullCitation>Yap TA, et al. J Clin Oncol (2020) pmid: 32568634</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>25686104</ReferenceId>
          <FullCitation>Bitler BG, et al. Nat. Med. (2015) pmid: 25686104</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>26552009</ReferenceId>
          <FullCitation>Kim KH, et al. Nat. Med. (2015) pmid: 26552009</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>24559118</ReferenceId>
          <FullCitation>Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>24336158</ReferenceId>
          <FullCitation>Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>24979463</ReferenceId>
          <FullCitation>Samartzis EP, et al. Oncotarget (2014) pmid: 24979463</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>24459582</ReferenceId>
          <FullCitation>Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>24833095</ReferenceId>
          <FullCitation>Xie C, et al. Tumour Biol. (2014) pmid: 24833095</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>23847781</ReferenceId>
          <FullCitation>Shiloh Y, et al. Nat. Rev. Mol. Cell Biol. (2013) pmid: 23847781</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>23851492</ReferenceId>
          <FullCitation>Cremona CA, et al. Oncogene (2014) pmid: 23851492</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>16603769</ReferenceId>
          <FullCitation>Jiang X, et al. J. Biol. Chem. (2006) pmid: 16603769</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>15713674</ReferenceId>
          <FullCitation>Fernandes N, et al. J. Biol. Chem. (2005) pmid: 15713674</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>11805335</ReferenceId>
          <FullCitation>Scott SP, et al. Proc. Natl. Acad. Sci. U.S.A. (2002) pmid: 11805335</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>21720365</ReferenceId>
          <FullCitation>Nature (2011) pmid: 21720365</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>24240112</ReferenceId>
          <FullCitation>Pennington KP, et al. Clin. Cancer Res. (2014) pmid: 24240112</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>24071502</ReferenceId>
          <FullCitation>Colombo PE, et al. Crit. Rev. Oncol. Hematol. (2014) pmid: 24071502</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>24752797</ReferenceId>
          <FullCitation>Ye Q, et al. Pathol. Oncol. Res. (2014) pmid: 24752797</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>22253870</ReferenceId>
          <FullCitation>Wysham WZ, et al. PLoS ONE (2012) pmid: 22253870</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>26674120</ReferenceId>
          <FullCitation>Abdel-Fatah TM, et al. BBA Clin (2014) pmid: 26674120</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>24037533</ReferenceId>
          <FullCitation>Michels J, et al. Oncogene (2014) pmid: 24037533</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>16556909</ReferenceId>
          <FullCitation>Bryant HE, et al. Nucleic Acids Res. (2006) pmid: 16556909</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>26510020</ReferenceId>
          <FullCitation>Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>31806540</ReferenceId>
          <FullCitation>Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>32086346</ReferenceId>
          <FullCitation>Abida W, et al. Clin. Cancer Res. (2020) pmid: 32086346</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>35004311</ReferenceId>
          <FullCitation>Papageorgiou GI, et al. Front Oncol (2021) pmid: 35004311</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>27079472</ReferenceId>
          <FullCitation>Olson D, et al. Clin Genitourin Cancer (2016) pmid: 27079472</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>33941784</ReferenceId>
          <FullCitation>Swisher EM, et al. Nat Commun (2021) pmid: 33941784</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>32045060</ReferenceId>
          <FullCitation>Zhang W, et al. Oncologist (2020) pmid: 32045060</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>32988960</ReferenceId>
          <FullCitation>Yap TA, et al. Cancer Discov (2021) pmid: 32988960</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>35790315</ReferenceId>
          <FullCitation>Kwon M, et al. J Immunother Cancer (2022) pmid: 35790315</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>25232030</ReferenceId>
          <FullCitation>Menezes DL, et al. Mol. Cancer Res. (2015) pmid: 25232030</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>26517239</ReferenceId>
          <FullCitation>Vendetti FP, et al. Oncotarget (2015) pmid: 26517239</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>28138034</ReferenceId>
          <FullCitation>Min A, et al. Mol. Cancer Ther. (2017) pmid: 28138034</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>26563132</ReferenceId>
          <FullCitation>Kwok M, et al. Blood (2016) pmid: 26563132</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>23761041</ReferenceId>
          <FullCitation>Riabinska A, et al. Sci Transl Med (2013) pmid: 23761041</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>29165669</ReferenceId>
          <FullCitation>Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>26662178</ReferenceId>
          <FullCitation>van Os NJ, et al. Clin Genet (2016) pmid: 26662178</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>27884168</ReferenceId>
          <FullCitation>Rothblum-Oviatt C, et al. Orphanet J Rare Dis (2016) pmid: 27884168</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>25426837</ReferenceId>
          <FullCitation>Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>25426838</ReferenceId>
          <FullCitation>Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>25326804</ReferenceId>
          <FullCitation>Xie M, et al. Nat. Med. (2014) pmid: 25326804</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>28669404</ReferenceId>
          <FullCitation>Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>29678827</ReferenceId>
          <FullCitation>Severson EA, et al. Blood (2018) pmid: 29678827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>29420212</ReferenceId>
          <FullCitation>Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>32269342</ReferenceId>
          <FullCitation>Chabon JJ, et al. Nature (2020) pmid: 32269342</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>31768066</ReferenceId>
          <FullCitation>Razavi P, et al. Nat. Med. (2019) pmid: 31768066</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>32919526</ReferenceId>
          <FullCitation>Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>31405947</ReferenceId>
          <FullCitation>Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>28835386</ReferenceId>
          <FullCitation>Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>30309915</ReferenceId>
          <FullCitation>Cristescu R, et al. Science (2018) pmid: 30309915</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>28420421</ReferenceId>
          <FullCitation>Chalmers ZR, et al. Genome Med (2017) pmid: 28420421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>26871470</ReferenceId>
          <FullCitation>Strickland KC, et al. Oncotarget (2016) pmid: 26871470</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>30643254</ReferenceId>
          <FullCitation>Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>30785829</ReferenceId>
          <FullCitation>Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>29658845</ReferenceId>
          <FullCitation>Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>29657128</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>29731394</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>33558721</ReferenceId>
          <FullCitation>Rozeman EA, et al. Nat Med (2021) pmid: 33558721</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>32916128</ReferenceId>
          <FullCitation>Sharma P, et al. Cancer Cell (2020) pmid: 32916128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>30557521</ReferenceId>
          <FullCitation>Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>35101941</ReferenceId>
          <FullCitation>Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>34876409</ReferenceId>
          <FullCitation>Friedman CF, et al. Cancer Discov (2022) pmid: 34876409</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>35274716</ReferenceId>
          <FullCitation>Sturgill EG, et al. Oncologist (2022) pmid: 35274716</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>27908594</ReferenceId>
          <FullCitation>Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>23047548</ReferenceId>
          <FullCitation>Abkevich V, et al. Br. J. Cancer (2012) pmid: 23047548</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>22912389</ReferenceId>
          <FullCitation>Wang ZC, et al. Clin. Cancer Res. (2012) pmid: 22912389</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>25093514</ReferenceId>
          <FullCitation>Watkins JA, et al. Breast Cancer Res. (2014) pmid: 25093514</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>28950147</ReferenceId>
          <FullCitation>Vanderstichele A, et al. Eur. J. Cancer (2017) pmid: 28950147</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>12736286</ReferenceId>
          <FullCitation>N. Engl. J. Med. (2003) pmid: 12736286</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="118">
          <ReferenceId>28916367</ReferenceId>
          <FullCitation>Coleman RL, et al. Lancet (2017) pmid: 28916367</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="119">
          <ReferenceId>26015868</ReferenceId>
          <FullCitation>Marquard AM, et al. Biomark Res (2015) pmid: 26015868</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="120">
          <ReferenceId>23716468</ReferenceId>
          <FullCitation>Pedersen BS, et al. Genes Chromosomes Cancer (2013) pmid: 23716468</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="121">
          <ReferenceId>27717299</ReferenceId>
          <FullCitation>Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="122">
          <ReferenceId>26957554</ReferenceId>
          <FullCitation>Telli ML, et al. Clin. Cancer Res. (2016) pmid: 26957554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="123">
          <ReferenceId>25475740</ReferenceId>
          <FullCitation>Timms KM, et al. Breast Cancer Res. (2014) pmid: 25475740</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="124">
          <ReferenceId>25847929</ReferenceId>
          <FullCitation>Telli ML, et al. J. Clin. Oncol. (2015) pmid: 25847929</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="125">
          <ReferenceId>25847936</ReferenceId>
          <FullCitation>Isakoff SJ, et al. J. Clin. Oncol. (2015) pmid: 25847936</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="126">
          <ReferenceId>21237710</ReferenceId>
          <FullCitation>Pritchett J, et al. Trends Mol Med (2011) pmid: 21237710</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="127">
          <ReferenceId>28481359</ReferenceId>
          <FullCitation>Zehir A, et al. Nat. Med. (2017) pmid: 28481359</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="128">
          <ReferenceId>28985567</ReferenceId>
          <FullCitation>Reddy A, et al. Cell (2017) pmid: 28985567</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="129">
          <ReferenceId>24030381</ReferenceId>
          <FullCitation>Papaemmanuil E, et al. Blood (2013) pmid: 24030381</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="130">
          <ReferenceId>30333627</ReferenceId>
          <FullCitation>Tyner JW, et al. Nature (2018) pmid: 30333627</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="131">
          <ReferenceId>27276561</ReferenceId>
          <FullCitation>Papaemmanuil E, et al. N. Engl. J. Med. (2016) pmid: 27276561</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="132">
          <ReferenceId>23201164</ReferenceId>
          <FullCitation>Kopp JL, et al. Cancer Cell (2012) pmid: 23201164</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="133">
          <ReferenceId>22703285</ReferenceId>
          <FullCitation>Zhong WD, et al. BMC Cancer (2012) pmid: 22703285</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="134">
          <ReferenceId>22714060</ReferenceId>
          <FullCitation>Wang L, et al. Med. Oncol. (2012) pmid: 22714060</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="135">
          <ReferenceId>23064761</ReferenceId>
          <FullCitation>Clemons NJ, et al. Am. J. Physiol. Gastrointest. Liver Physiol. (2012) pmid: 23064761</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="136">
          <ReferenceId>15231737</ReferenceId>
          <FullCitation>Kirmizis A, et al. Genes Dev. (2004) pmid: 15231737</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="137">
          <ReferenceId>15099518</ReferenceId>
          <FullCitation>Kuzmichev A, et al. Mol. Cell (2004) pmid: 15099518</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="138">
          <ReferenceId>15385962</ReferenceId>
          <FullCitation>Pasini D, et al. EMBO J. (2004) pmid: 15385962</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="139">
          <ReferenceId>17200670</ReferenceId>
          <FullCitation>Schlesinger Y, et al. Nat. Genet. (2007) pmid: 17200670</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="140">
          <ReferenceId>24457600</ReferenceId>
          <FullCitation>Cao Q, et al. Nat Commun (2014) pmid: 24457600</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="141">
          <ReferenceId>22475286</ReferenceId>
          <FullCitation>Xu F, et al. Expert Rev Hematol (2012) pmid: 22475286</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="142">
          <ReferenceId>21367748</ReferenceId>
          <FullCitation>Chase A, et al. Clin. Cancer Res. (2011) pmid: 21367748</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="143">
          <ReferenceId>27000413</ReferenceId>
          <FullCitation>Jain P, et al. Bioessays (2016) pmid: 27000413</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="144">
          <ReferenceId>25305755</ReferenceId>
          <FullCitation>Zhang M, et al. Nat. Genet. (2014) pmid: 25305755</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="145">
          <ReferenceId>26497635</ReferenceId>
          <FullCitation>Conway E, et al. Curr. Opin. Cell Biol. (2015) pmid: 26497635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="146">
          <ReferenceId>25240281</ReferenceId>
          <FullCitation>Lee W, et al. Nat. Genet. (2014) pmid: 25240281</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="147">
          <ReferenceId>25119042</ReferenceId>
          <FullCitation>De Raedt T, et al. Nature (2014) pmid: 25119042</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="148">
          <ReferenceId>25079552</ReferenceId>
          <FullCitation>Nature (2014) pmid: 25079552</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="149">
          <ReferenceId>26928463</ReferenceId>
          <FullCitation>Kumar A, et al. Nat. Med. (2016) pmid: 26928463</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="150">
          <ReferenceId>24476821</ReferenceId>
          <FullCitation>Nature (2014) pmid: 24476821</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="151">
          <ReferenceId>25631445</ReferenceId>
          <FullCitation>Nature (2015) pmid: 25631445</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="152">
          <ReferenceId>28776573</ReferenceId>
          <FullCitation>Basturk O, et al. Mod. Pathol. (2017) pmid: 28776573</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="153">
          <ReferenceId>22733077</ReferenceId>
          <FullCitation>Ueda T, et al. Leukemia (2012) pmid: 22733077</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="154">
          <ReferenceId>27471434</ReferenceId>
          <FullCitation>Ramaglia M, et al. Cancer Cell Int. (2016) pmid: 27471434</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="155">
          <ReferenceId>29415665</ReferenceId>
          <FullCitation>Cho YJ, et al. BMC Cancer (2018) pmid: 29415665</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="156">
          <ReferenceId>27311868</ReferenceId>
          <FullCitation>Abdalkader L, et al. Pathology (2016) pmid: 27311868</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="157">
          <ReferenceId>28254486</ReferenceId>
          <FullCitation>Curtin ML, et al. Bioorg. Med. Chem. Lett. (2017) pmid: 28254486</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="158">
          <ReferenceId>28135237</ReferenceId>
          <FullCitation>He Y, et al. Nat. Chem. Biol. (2017) pmid: 28135237</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="159">
          <ReferenceId>28135235</ReferenceId>
          <FullCitation>Qi W, et al. Nat. Chem. Biol. (2017) pmid: 28135235</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="160">
          <ReferenceId>28092155</ReferenceId>
          <FullCitation>Huang Y, et al. J. Med. Chem. (2017) pmid: 28092155</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="161">
          <ReferenceId>28165227</ReferenceId>
          <FullCitation>Barnash KD, et al. ACS Comb Sci (2017) pmid: 28165227</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="162">
          <ReferenceId>28072869</ReferenceId>
          <FullCitation>Li L, et al. PLoS ONE (2017) pmid: 28072869</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="163">
          <ReferenceId>19563753</ReferenceId>
          <FullCitation>Phillips JE, et al. Cell (2009) pmid: 19563753</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="164">
          <ReferenceId>19568426</ReferenceId>
          <FullCitation>Gombert WM, et al. PLoS ONE (2009) pmid: 19568426</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="165">
          <ReferenceId>20101205</ReferenceId>
          <FullCitation>Soto-Reyes E, et al. Oncogene (2010) pmid: 20101205</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="166">
          <ReferenceId>21296871</ReferenceId>
          <FullCitation>Woloszynska-Read A, et al. Clin. Cancer Res. (2011) pmid: 21296871</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="167">
          <ReferenceId>24794443</ReferenceId>
          <FullCitation>Kemp CJ, et al. Cell Rep (2014) pmid: 24794443</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="168">
          <ReferenceId>23908591</ReferenceId>
          <FullCitation>Méndez-Catalá CF, et al. Neoplasia (2013) pmid: 23908591</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="169">
          <ReferenceId>23553099</ReferenceId>
          <FullCitation>Tiffen JC, et al. Int. J. Cancer (2013) pmid: 23553099</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="170">
          <ReferenceId>12393275</ReferenceId>
          <FullCitation>Lee CJ, et al. Brain Res. Mol. Brain Res. (2002) pmid: 12393275</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="171">
          <ReferenceId>21817013</ReferenceId>
          <FullCitation>Bettegowda C, et al. Science (2011) pmid: 21817013</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="172">
          <ReferenceId>22072542</ReferenceId>
          <FullCitation>Yip S, et al. J. Pathol. (2012) pmid: 22072542</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="173">
          <ReferenceId>22588899</ReferenceId>
          <FullCitation>Sahm F, et al. Acta Neuropathol. (2012) pmid: 22588899</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="174">
          <ReferenceId>22869205</ReferenceId>
          <FullCitation>Jiao Y, et al. Oncotarget (2012) pmid: 22869205</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="175">
          <ReferenceId>24030748</ReferenceId>
          <FullCitation>Chan AK, et al. Mod. Pathol. (2014) pmid: 24030748</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="176">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="177">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="178">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="179">
          <ReferenceId>9823339</ReferenceId>
          <FullCitation>Boland CR, et al. Cancer Res. (1998) pmid: 9823339</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="180">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="181">
          <ReferenceId>20420947</ReferenceId>
          <FullCitation>Boland CR, et al. Gastroenterology (2010) pmid: 20420947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="182">
          <ReferenceId>26775351</ReferenceId>
          <FullCitation>Segev Y, et al. Eur. J. Gynaecol. Oncol. (2015) pmid: 26775351</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="183">
          <ReferenceId>18507046</ReferenceId>
          <FullCitation>Plisiecka-Hałasa J, et al. Anticancer Res. () pmid: 18507046</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="184">
          <ReferenceId>22189970</ReferenceId>
          <FullCitation>Aysal A, et al. Am. J. Surg. Pathol. (2012) pmid: 22189970</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="185">
          <ReferenceId>17204026</ReferenceId>
          <FullCitation>Histopathology (2007) pmid: 17204026</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="186">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="187">
          <ReferenceId>28734759</ReferenceId>
          <FullCitation>Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="188">
          <ReferenceId>29355075</ReferenceId>
          <FullCitation>Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="189">
          <ReferenceId>35322232</ReferenceId>
          <FullCitation>Shitara K, et al. Nature (2022) pmid: 35322232</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="190">
          <ReferenceId>23169436</ReferenceId>
          <FullCitation>Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="191">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="192">
          <ReferenceId>33001143</ReferenceId>
          <FullCitation>Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="193">
          <ReferenceId>36512912</ReferenceId>
          <FullCitation>Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="194">
          <ReferenceId>33811152</ReferenceId>
          <FullCitation>Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="195">
          <ReferenceId>19659756</ReferenceId>
          <FullCitation>Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="196">
          <ReferenceId>22714864</ReferenceId>
          <FullCitation>Pande M, et al. Fam. Cancer (2012) pmid: 22714864</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="197">
          <ReferenceId>17920897</ReferenceId>
          <FullCitation>Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="198">
          <ReferenceId>19466295</ReferenceId>
          <FullCitation>Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="199">
          <ReferenceId>24978665</ReferenceId>
          <FullCitation>Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="200">
          <ReferenceId>16136383</ReferenceId>
          <FullCitation>Fam. Cancer (2005) pmid: 16136383</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="201">
          <ReferenceId>21654818</ReferenceId>
          <FullCitation>Wilson BG, et al. Nat. Rev. Cancer (2011) pmid: 21654818</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="202">
          <ReferenceId>23355908</ReferenceId>
          <FullCitation>Shain AH, et al. PLoS ONE (2013) pmid: 23355908</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="203">
          <ReferenceId>18086889</ReferenceId>
          <FullCitation>Trotter KW, et al. Mol. Cell. Biol. (2008) pmid: 18086889</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="204">
          <ReferenceId>17274598</ReferenceId>
          <FullCitation>Shen W, et al. Biochemistry (2007) pmid: 17274598</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="205">
          <ReferenceId>23698369</ReferenceId>
          <FullCitation>Dykhuizen EC, et al. Nature (2013) pmid: 23698369</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="206">
          <ReferenceId>27941795</ReferenceId>
          <FullCitation>Stanton BZ, et al. Nat. Genet. (2017) pmid: 27941795</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="207">
          <ReferenceId>33144586</ReferenceId>
          <FullCitation>Fernando TM, et al. Nat Commun (2020) pmid: 33144586</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="208">
          <ReferenceId>26645725</ReferenceId>
          <FullCitation>Conlon N, et al. Am J Surg Pathol (2016) pmid: 26645725</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="209">
          <ReferenceId>24658004</ReferenceId>
          <FullCitation>Jelinic P, et al. Nat. Genet. (2014) pmid: 24658004</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="210">
          <ReferenceId>24658002</ReferenceId>
          <FullCitation>Witkowski L, et al. Nat. Genet. (2014) pmid: 24658002</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="211">
          <ReferenceId>24658001</ReferenceId>
          <FullCitation>Ramos P, et al. Nat. Genet. (2014) pmid: 24658001</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="212">
          <ReferenceId>29102090</ReferenceId>
          <FullCitation>Lin DI, et al. Gynecol. Oncol. (2017) pmid: 29102090</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="213">
          <ReferenceId>32575483</ReferenceId>
          <FullCitation>Auguste A, et al. Cells (2020) pmid: 32575483</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="214">
          <ReferenceId>25307865</ReferenceId>
          <FullCitation>Bailey S, et al. Pediatr Blood Cancer (2015) pmid: 25307865</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="215">
          <ReferenceId>24375037</ReferenceId>
          <FullCitation>Kupryjańczyk J, et al. Pol J Pathol (2013) pmid: 24375037</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="216">
          <ReferenceId>26356327</ReferenceId>
          <FullCitation>Karnezis AN, et al. J. Pathol. (2016) pmid: 26356327</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="217">
          <ReferenceId>29650362</ReferenceId>
          <FullCitation>Italiano A, et al. Lancet Oncol. (2018) pmid: 29650362</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="218">
          <ReferenceId>30718512</ReferenceId>
          <FullCitation>Xue Y, et al. Nat Commun (2019) pmid: 30718512</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="219">
          <ReferenceId>30718506</ReferenceId>
          <FullCitation>Xue Y, et al. Nat Commun (2019) pmid: 30718506</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="220">
          <ReferenceId>32704608</ReferenceId>
          <FullCitation>Lee EK, et al. JCO Precis Oncol (2020) pmid: 32704608</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="221">
          <ReferenceId>31617320</ReferenceId>
          <FullCitation>Takada K, et al. Thorac Cancer (2019) pmid: 31617320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="222">
          <ReferenceId>3577899</ReferenceId>
          <FullCitation>Congia S, et al. Adv Exp Med Biol (1987) pmid: 3577899</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="223">
          <ReferenceId>34746887</ReferenceId>
          <FullCitation>Kunimasa K, et al. JTO Clin Res Rep (2021) pmid: 34746887</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="224">
          <ReferenceId>34030451</ReferenceId>
          <FullCitation>Kawachi H, et al. Immunotherapy (2021) pmid: 34030451</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="225">
          <ReferenceId>18418043</ReferenceId>
          <FullCitation>Huang CH, et al. Cell Cycle (2008) pmid: 18418043</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="226">
          <ReferenceId>20530665</ReferenceId>
          <FullCitation>Taniguchi CM, et al. Cancer Res. (2010) pmid: 20530665</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="227">
          <ReferenceId>16679293</ReferenceId>
          <FullCitation>Luo J, et al. Cell Metab. (2006) pmid: 16679293</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="228">
          <ReferenceId>14504291</ReferenceId>
          <FullCitation>Ueki K, et al. J. Biol. Chem. (2003) pmid: 14504291</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="229">
          <ReferenceId>11781359</ReferenceId>
          <FullCitation>Mauvais-Jarvis F, et al. J. Clin. Invest. (2002) pmid: 11781359</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="230">
          <ReferenceId>28630349</ReferenceId>
          <FullCitation>Thorpe LM, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28630349</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="231">
          <ReferenceId>30755611</ReferenceId>
          <FullCitation>Li X, et al. Nat Commun (2019) pmid: 30755611</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="232">
          <ReferenceId>16006513</ReferenceId>
          <FullCitation>Luo J, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16006513</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="233">
          <ReferenceId>19962665</ReferenceId>
          <FullCitation>Jaiswal BS, et al. Cancer Cell (2009) pmid: 19962665</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="234">
          <ReferenceId>21984976</ReferenceId>
          <FullCitation>Cheung LW, et al. Cancer Discov (2011) pmid: 21984976</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="235">
          <ReferenceId>24651434</ReferenceId>
          <FullCitation>Ko HR, et al. Cell Death Dis (2014) pmid: 24651434</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="236">
          <ReferenceId>23166678</ReferenceId>
          <FullCitation>Quayle SN, et al. PLoS ONE (2012) pmid: 23166678</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="237">
          <ReferenceId>20713702</ReferenceId>
          <FullCitation>Sun M, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20713702</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="238">
          <ReferenceId>19915146</ReferenceId>
          <FullCitation>Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="239">
          <ReferenceId>21478295</ReferenceId>
          <FullCitation>Urick ME, et al. Cancer Res. (2011) pmid: 21478295</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="240">
          <ReferenceId>18079394</ReferenceId>
          <FullCitation>Huang CH, et al. Science (2007) pmid: 18079394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="241">
          <ReferenceId>16917505</ReferenceId>
          <FullCitation>Bousquet C, et al. EMBO J. (2006) pmid: 16917505</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="242">
          <ReferenceId>28143957</ReferenceId>
          <FullCitation>Oliver MD, et al. Biosci. Rep. (2017) pmid: 28143957</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="243">
          <ReferenceId>11606375</ReferenceId>
          <FullCitation>Philp AJ, et al. Cancer Res. (2001) pmid: 11606375</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="244">
          <ReferenceId>25488983</ReferenceId>
          <FullCitation>Lucas CL, et al. J. Exp. Med. (2014) pmid: 25488983</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="245">
          <ReferenceId>29636477</ReferenceId>
          <FullCitation>Chen L, et al. Nat Commun (2018) pmid: 29636477</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="246">
          <ReferenceId>25284480</ReferenceId>
          <FullCitation>Cheung LW, et al. Cancer Cell (2014) pmid: 25284480</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="247">
          <ReferenceId>34507989</ReferenceId>
          <FullCitation>Li X, et al. Proc Natl Acad Sci U S A (2021) pmid: 34507989</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="248">
          <ReferenceId>24120142</ReferenceId>
          <FullCitation>Brennan CW, et al. Cell (2013) pmid: 24120142</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="249">
          <ReferenceId>26061751</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="250">
          <ReferenceId>26657142</ReferenceId>
          <FullCitation>Ye K, et al. Nat. Med. (2016) pmid: 26657142</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="251">
          <ReferenceId>26501081</ReferenceId>
          <FullCitation>Munkley J, et al. Oncoscience (2015) pmid: 26501081</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="252">
          <ReferenceId>24229379</ReferenceId>
          <FullCitation>Cizkova M, et al. BMC Cancer (2013) pmid: 24229379</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="253">
          <ReferenceId>23980085</ReferenceId>
          <FullCitation>Qian ZR, et al. J. Clin. Oncol. (2013) pmid: 23980085</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="254">
          <ReferenceId>25528496</ReferenceId>
          <FullCitation>Matulonis U, et al. Gynecol. Oncol. (2015) pmid: 25528496</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="255">
          <ReferenceId>25605819</ReferenceId>
          <FullCitation>Pitz MW, et al. Neuro-oncology (2015) pmid: 25605819</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="256">
          <ReferenceId>27893038</ReferenceId>
          <FullCitation>Basho RK, et al. JAMA Oncol (2017) pmid: 27893038</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="257">
          <ReferenceId>27016228</ReferenceId>
          <FullCitation>Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="258">
          <ReferenceId>30420444</ReferenceId>
          <FullCitation>Day TA, et al. Clin. Cancer Res. (2019) pmid: 30420444</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="259">
          <ReferenceId>25193464</ReferenceId>
          <FullCitation>Ou O, et al. Cancer Lett. (2014) pmid: 25193464</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="260">
          <ReferenceId>23622243</ReferenceId>
          <FullCitation>Li F, et al. Cell (2013) pmid: 23622243</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="261">
          <ReferenceId>21720545</ReferenceId>
          <FullCitation>Wu H, et al. PLoS ONE (2011) pmid: 21720545</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="262">
          <ReferenceId>23391514</ReferenceId>
          <FullCitation>Edelbrock MA, et al. Mutat. Res. () pmid: 23391514</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="263">
          <ReferenceId>11709755</ReferenceId>
          <FullCitation>Berends MJ, et al. Am. J. Hum. Genet. (2002) pmid: 11709755</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="264">
          <ReferenceId>17531815</ReferenceId>
          <FullCitation>Warren JJ, et al. Mol. Cell (2007) pmid: 17531815</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="265">
          <ReferenceId>22277660</ReferenceId>
          <FullCitation>Geng H, et al. J. Biol. Chem. (2012) pmid: 22277660</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="266">
          <ReferenceId>21642682</ReferenceId>
          <FullCitation>Bonadona V, et al. JAMA (2011) pmid: 21642682</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="267">
          <ReferenceId>25504677</ReferenceId>
          <FullCitation>Joly MO, et al. Hum. Mutat. (2015) pmid: 25504677</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="268">
          <ReferenceId>25255306</ReferenceId>
          <FullCitation>Pritchard CC, et al. Nat Commun (2014) pmid: 25255306</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="269">
          <ReferenceId>25117503</ReferenceId>
          <FullCitation>Rosty C, et al. Fam. Cancer (2014) pmid: 25117503</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="270">
          <ReferenceId>25636458</ReferenceId>
          <FullCitation>McConechy MK, et al. Gynecol. Oncol. (2015) pmid: 25636458</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="271">
          <ReferenceId>25392179</ReferenceId>
          <FullCitation>Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="272">
          <ReferenceId>16083711</ReferenceId>
          <FullCitation>Raevaara TE, et al. Gastroenterology (2005) pmid: 16083711</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="273">
          <ReferenceId>18709565</ReferenceId>
          <FullCitation>Wimmer K, et al. Hum. Genet. (2008) pmid: 18709565</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="274">
          <ReferenceId>24737826</ReferenceId>
          <FullCitation>Wimmer K, et al. J. Med. Genet. (2014) pmid: 24737826</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="275">
          <ReferenceId>17259933</ReferenceId>
          <FullCitation>Scott RH, et al. Nat Clin Pract Oncol (2007) pmid: 17259933</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="276">
          <ReferenceId>20015892</ReferenceId>
          <FullCitation>Ripperger T, et al. Haematologica (2010) pmid: 20015892</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="277">
          <ReferenceId>26544533</ReferenceId>
          <FullCitation>Baris HN, et al. Pediatr Blood Cancer (2016) pmid: 26544533</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="278">
          <ReferenceId>11237521</ReferenceId>
          <FullCitation>Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="279">
          <ReferenceId>12857747</ReferenceId>
          <FullCitation>Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="280">
          <ReferenceId>21828076</ReferenceId>
          <FullCitation>Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="281">
          <ReferenceId>23475934</ReferenceId>
          <FullCitation>He X, et al. Cancer Res. (2013) pmid: 23475934</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="282">
          <ReferenceId>10866302</ReferenceId>
          <FullCitation>Han SY, et al. Cancer Res. (2000) pmid: 10866302</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="283">
          <ReferenceId>9811831</ReferenceId>
          <FullCitation>Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="284">
          <ReferenceId>24498881</ReferenceId>
          <FullCitation>Pradella LM, et al. BMC Cancer (2014) pmid: 24498881</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="285">
          <ReferenceId>21536651</ReferenceId>
          <FullCitation>Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="286">
          <ReferenceId>17213812</ReferenceId>
          <FullCitation>Denning G, et al. Oncogene (2007) pmid: 17213812</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="287">
          <ReferenceId>16619501</ReferenceId>
          <FullCitation>Hlobilkova A, et al. Anticancer Res. () pmid: 16619501</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="288">
          <ReferenceId>20718038</ReferenceId>
          <FullCitation>Redfern RE, et al. Protein Sci. (2010) pmid: 20718038</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="289">
          <ReferenceId>22505997</ReferenceId>
          <FullCitation>Shenoy S, et al. PLoS ONE (2012) pmid: 22505997</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="290">
          <ReferenceId>19329485</ReferenceId>
          <FullCitation>Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="291">
          <ReferenceId>16829519</ReferenceId>
          <FullCitation>Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="292">
          <ReferenceId>10555148</ReferenceId>
          <FullCitation>Lee JO, et al. Cell (1999) pmid: 10555148</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="293">
          <ReferenceId>9635567</ReferenceId>
          <FullCitation>Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="294">
          <ReferenceId>9865913</ReferenceId>
          <FullCitation>Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="295">
          <ReferenceId>11051241</ReferenceId>
          <FullCitation>Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="296">
          <ReferenceId>22891331</ReferenceId>
          <FullCitation>Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="297">
          <ReferenceId>23066114</ReferenceId>
          <FullCitation>Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="298">
          <ReferenceId>19457929</ReferenceId>
          <FullCitation>Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="299">
          <ReferenceId>23995781</ReferenceId>
          <FullCitation>Liu J, et al. Oncogene (2014) pmid: 23995781</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="300">
          <ReferenceId>11395408</ReferenceId>
          <FullCitation>Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="301">
          <ReferenceId>10807691</ReferenceId>
          <FullCitation>De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="302">
          <ReferenceId>10051603</ReferenceId>
          <FullCitation>Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="303">
          <ReferenceId>15988030</ReferenceId>
          <FullCitation>Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="304">
          <ReferenceId>15026806</ReferenceId>
          <FullCitation>Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="305">
          <ReferenceId>25875300</ReferenceId>
          <FullCitation>Gil A, et al. PLoS ONE (2015) pmid: 25875300</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="306">
          <ReferenceId>9823298</ReferenceId>
          <FullCitation>Furnari FB, et al. Cancer Res. (1998) pmid: 9823298</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="307">
          <ReferenceId>25527629</ReferenceId>
          <FullCitation>Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="308">
          <ReferenceId>29706633</ReferenceId>
          <FullCitation>Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="309">
          <ReferenceId>20538496</ReferenceId>
          <FullCitation>Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="310">
          <ReferenceId>17942903</ReferenceId>
          <FullCitation>Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="311">
          <ReferenceId>15805158</ReferenceId>
          <FullCitation>Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="312">
          <ReferenceId>10468583</ReferenceId>
          <FullCitation>Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="313">
          <ReferenceId>12085208</ReferenceId>
          <FullCitation>Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="314">
          <ReferenceId>24292679</ReferenceId>
          <FullCitation>Nguyen HN, et al. Oncogene (2014) pmid: 24292679</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="315">
          <ReferenceId>19114656</ReferenceId>
          <FullCitation>Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="316">
          <ReferenceId>12808147</ReferenceId>
          <FullCitation>Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="317">
          <ReferenceId>18498243</ReferenceId>
          <FullCitation>Wang X, et al. Biochem. J. (2008) pmid: 18498243</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="318">
          <ReferenceId>15951562</ReferenceId>
          <FullCitation>Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="319">
          <ReferenceId>25263454</ReferenceId>
          <FullCitation>Nguyen HN, et al. Oncogene (2015) pmid: 25263454</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="320">
          <ReferenceId>32704382</ReferenceId>
          <FullCitation>Shan L, et al. Cell Discov (2020) pmid: 32704382</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="321">
          <ReferenceId>9605750</ReferenceId>
          <FullCitation>Obata K, et al. Cancer Res. (1998) pmid: 9605750</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="322">
          <ReferenceId>30979843</ReferenceId>
          <FullCitation>Hauke J, et al. J Med Genet (2019) pmid: 30979843</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="323">
          <ReferenceId>23765252</ReferenceId>
          <FullCitation>McConechy MK, et al. Mod. Pathol. (2014) pmid: 23765252</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="324">
          <ReferenceId>16525657</ReferenceId>
          <FullCitation>Sui L, et al. Oncol. Rep. (2006) pmid: 16525657</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="325">
          <ReferenceId>19150122</ReferenceId>
          <FullCitation>Lee YK, et al. Gynecol. Oncol. (2009) pmid: 19150122</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="326">
          <ReferenceId>23962610</ReferenceId>
          <FullCitation>Lai CR, et al. J Chin Med Assoc (2013) pmid: 23962610</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="327">
          <ReferenceId>21792012</ReferenceId>
          <FullCitation>Skírnisdóttir I, et al. Int. J. Gynecol. Cancer (2011) pmid: 21792012</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="328">
          <ReferenceId>20085938</ReferenceId>
          <FullCitation>Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="329">
          <ReferenceId>27672108</ReferenceId>
          <FullCitation>Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="330">
          <ReferenceId>28220839</ReferenceId>
          <FullCitation>Milella M, et al. Sci Rep (2017) pmid: 28220839</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="331">
          <ReferenceId>23582881</ReferenceId>
          <FullCitation>Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="332">
          <ReferenceId>34246347</ReferenceId>
          <FullCitation>Sweeney C, et al. Lancet (2021) pmid: 34246347</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="333">
          <ReferenceId>30037818</ReferenceId>
          <FullCitation>de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="334">
          <ReferenceId>27872130</ReferenceId>
          <FullCitation>Saura C, et al. Cancer Discov (2017) pmid: 27872130</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="335">
          <ReferenceId>30327302</ReferenceId>
          <FullCitation>Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="336">
          <ReferenceId>27091708</ReferenceId>
          <FullCitation>André F, et al. J. Clin. Oncol. (2016) pmid: 27091708</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="337">
          <ReferenceId>34264439</ReferenceId>
          <FullCitation>Dent R, et al. Breast Cancer Res Treat (2021) pmid: 34264439</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="338">
          <ReferenceId>31841354</ReferenceId>
          <FullCitation>Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="339">
          <ReferenceId>30302599</ReferenceId>
          <FullCitation>Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="340">
          <ReferenceId>20049735</ReferenceId>
          <FullCitation>Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="341">
          <ReferenceId>23881923</ReferenceId>
          <FullCitation>Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="342">
          <ReferenceId>23565244</ReferenceId>
          <FullCitation>Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="343">
          <ReferenceId>26905328</ReferenceId>
          <FullCitation>McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="344">
          <ReferenceId>21468130</ReferenceId>
          <FullCitation>Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="345">
          <ReferenceId>33242536</ReferenceId>
          <FullCitation>Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="346">
          <ReferenceId>33970096</ReferenceId>
          <FullCitation>Pan M, et al. Perm J (2021) pmid: 33970096</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="347">
          <ReferenceId>23810788</ReferenceId>
          <FullCitation>Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="348">
          <ReferenceId>32988624</ReferenceId>
          <FullCitation>Romero I, et al. Gynecol Oncol (2020) pmid: 32988624</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="349">
          <ReferenceId>32532747</ReferenceId>
          <FullCitation>Yap TA, et al. Cancer Discov (2020) pmid: 32532747</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="350">
          <ReferenceId>18781191</ReferenceId>
          <FullCitation>Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="351">
          <ReferenceId>18794875</ReferenceId>
          <FullCitation>Orloff MS, et al. Oncogene (2008) pmid: 18794875</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="352">
          <ReferenceId>17167516</ReferenceId>
          <FullCitation>Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="353">
          <ReferenceId>34083238</ReferenceId>
          <FullCitation>Marcus L, et al. Clin Cancer Res (2021) pmid: 34083238</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="354">
          <ReferenceId>32275468</ReferenceId>
          <FullCitation>Zamarin D, et al. J. Clin. Oncol. (2020) pmid: 32275468</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="355">
          <ReferenceId>33856094</ReferenceId>
          <FullCitation>Klein O, et al. Oncologist (2021) pmid: 33856094</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="356">
          <ReferenceId>33889439</ReferenceId>
          <FullCitation>Klein O, et al. Oncoimmunology (2021) pmid: 33889439</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="357">
          <ReferenceId>30676622</ReferenceId>
          <FullCitation>Disis ML, et al. JAMA Oncol (2019) pmid: 30676622</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="358">
          <ReferenceId>34143970</ReferenceId>
          <FullCitation>Pujade-Lauraine E, et al. Lancet Oncol (2021) pmid: 34143970</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="359">
          <ReferenceId>34363762</ReferenceId>
          <FullCitation>Monk BJ, et al. Lancet Oncol (2021) pmid: 34363762</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="360">
          <ReferenceId>26351349</ReferenceId>
          <FullCitation>Hamanishi J, et al. J. Clin. Oncol. (2015) pmid: 26351349</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="361">
          <ReferenceId>31074244</ReferenceId>
          <FullCitation>Normann MC, et al. J Gynecol Oncol (2019) pmid: 31074244</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="362">
          <ReferenceId>31600397</ReferenceId>
          <FullCitation>Liu JF, et al. JAMA Oncol (2019) pmid: 31600397</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="363">
          <ReferenceId>22658128</ReferenceId>
          <FullCitation>Brahmer JR, et al. N. Engl. J. Med. (2012) pmid: 22658128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="364">
          <ReferenceId>29998185</ReferenceId>
          <FullCitation>Matsuo K, et al. Gynecol Oncol Rep (2018) pmid: 29998185</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="365">
          <ReferenceId>35320892</ReferenceId>
          <FullCitation>Lee JY, et al. J Gynecol Oncol (2022) pmid: 35320892</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="366">
          <ReferenceId>31204078</ReferenceId>
          <FullCitation>Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31204078</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="367">
          <ReferenceId>32723836</ReferenceId>
          <FullCitation>Moroney JW, et al. Clin Cancer Res (2020) pmid: 32723836</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="368">
          <ReferenceId>33891472</ReferenceId>
          <FullCitation>Moore KN, et al. J Clin Oncol (2021) pmid: 33891472</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="369">
          <ReferenceId>33458824</ReferenceId>
          <FullCitation>Ak N, et al. J Clin Pharm Ther (2021) pmid: 33458824</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="370">
          <ReferenceId>35816951</ReferenceId>
          <FullCitation>Rao S, et al. ESMO Open (2022) pmid: 35816951</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="371">
          <ReferenceId>36029651</ReferenceId>
          <FullCitation>Catenacci DVT, et al. ESMO Open (2022) pmid: 36029651</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="372">
          <ReferenceId>29863979</ReferenceId>
          <FullCitation>Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="373">
          <ReferenceId>31046082</ReferenceId>
          <FullCitation>Matulonis UA, et al. Ann. Oncol. (2019) pmid: 31046082</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="374">
          <ReferenceId>30522700</ReferenceId>
          <FullCitation>Varga A, et al. Gynecol. Oncol. (2019) pmid: 30522700</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="375">
          <ReferenceId>31194228</ReferenceId>
          <FullCitation>Konstantinopoulos PA, et al. JAMA Oncol (2019) pmid: 31194228</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="376">
          <ReferenceId>35680043</ReferenceId>
          <FullCitation>Maio M, et al. Ann Oncol (2022) pmid: 35680043</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2023-06-16 23:52:11</ServerTime>
          <OpName>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>866x</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>14 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>2.6%</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease-ontology="Unspecified primary endometrioid carcinoma" flowcell-analysis="2000029547" gender="female" pathology-diagnosis="Adenocarcinoma" percent-tumor-nuclei="40" pipeline-version="v3.23.0" purity-assessment="70.2" specimen="ORD-1648396-01*US1572255.01" study="CLINICAL-F1CDx v2" test-request="ORD-1648396-01" test-type="FoundationOneDx" tissue-of-origin="Pelvis" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="DX2" mean-exon-depth="882.53" name="SQ-US1572255.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.4929" cds-effect="1481C&gt;T" depth="631" equivocal="false" functional-effect="missense" gene="DIS3" percent-reads="49.29" position="chr13:73345967" protein-effect="A494V" status="unknown" strand="-" transcript="NM_001128226">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3442" cds-effect="326delC" depth="462" equivocal="false" functional-effect="frameshift" gene="SMARCA4" percent-reads="34.42" position="chr19:11096051" protein-effect="P109fs*194" status="likely" strand="+" transcript="NM_003072">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3685" cds-effect="916delG" depth="559" equivocal="false" functional-effect="frameshift" gene="SOX9" percent-reads="36.85" position="chr17:70119913" protein-effect="V306fs*77" status="likely" strand="+" transcript="NM_000346">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3429" cds-effect="124G&gt;A" depth="487" equivocal="false" functional-effect="missense" gene="FH" percent-reads="34.29" position="chr1:241682899" protein-effect="A42T" status="unknown" strand="-" transcript="NM_000143">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3392" cds-effect="1751G&gt;T" depth="858" equivocal="false" functional-effect="missense" gene="EPHA3" percent-reads="33.92" position="chr3:89457270" protein-effect="G584V" status="unknown" strand="+" transcript="NM_005233">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.2585" cds-effect="1801_1813delGAAAACACTGAAG" depth="1064" equivocal="false" functional-effect="frameshift" gene="PIK3R1" percent-reads="25.85" position="chr5:67591302" protein-effect="E601fs*57" status="likely" strand="+" transcript="NM_181523">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3086" cds-effect="3743delC" depth="538" equivocal="false" functional-effect="frameshift" gene="CIC" percent-reads="30.86" position="chr19:42797380" protein-effect="P1248fs*54" status="known" strand="+" transcript="NM_015125">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3262" cds-effect="1354_1357TATA&gt;C" depth="653" equivocal="false" functional-effect="nonframeshift" gene="PIK3R1" percent-reads="32.62" position="chr5:67589591" protein-effect="Y452_N453&gt;H" status="known" strand="+" transcript="NM_181523">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3178" cds-effect="1711delC" depth="623" equivocal="false" functional-effect="frameshift" gene="CIC" percent-reads="31.78" position="chr19:42794630" protein-effect="L571fs*157" status="likely" strand="+" transcript="NM_015125">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3607" cds-effect="161C&gt;T" depth="718" equivocal="false" functional-effect="missense" gene="GNAQ" percent-reads="36.07" position="chr9:80537237" protein-effect="T54M" status="unknown" strand="-" transcript="NM_002072">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0931" cds-effect="3261delC" depth="623" equivocal="false" functional-effect="frameshift" gene="MSH6" percent-reads="9.31" position="chr2:48030646" protein-effect="F1088fs*2" status="known" strand="+" transcript="NM_000179">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.2178" cds-effect="955_958delACTT" depth="473" equivocal="false" functional-effect="frameshift" gene="PTEN" percent-reads="21.78" position="chr10:89720803" protein-effect="T319fs*1" status="known" strand="+" transcript="NM_000314">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3344" cds-effect="5270G&gt;A" depth="655" equivocal="false" functional-effect="missense" gene="POLE" percent-reads="33.44" position="chr12:133218341" protein-effect="S1757N" status="unknown" strand="-" transcript="NM_006231">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.47" cds-effect="1913C&gt;T" depth="832" equivocal="false" functional-effect="missense" gene="EGFR" percent-reads="47.0" position="chr7:55238900" protein-effect="T638M" status="unknown" strand="+" transcript="NM_005228">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5097" cds-effect="992C&gt;T" depth="618" equivocal="false" functional-effect="missense" gene="FLCN" percent-reads="50.97" position="chr17:17122403" protein-effect="S331F" status="unknown" strand="-" transcript="NM_144997">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3971" cds-effect="751_752insA" depth="544" equivocal="false" functional-effect="frameshift" gene="EED" percent-reads="39.71" position="chr11:85977149" protein-effect="I251fs*11" status="likely" strand="+" transcript="NM_003797">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3275" cds-effect="640_641insT" depth="626" equivocal="false" functional-effect="frameshift" gene="ATM" percent-reads="32.75" position="chr11:108114823" protein-effect="S214fs*40" status="likely" strand="+" transcript="NM_000051">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3408" cds-effect="971delG" depth="402" equivocal="false" functional-effect="frameshift" gene="ARID1A" percent-reads="34.08" position="chr1:27023864" protein-effect="G324fs*39" status="likely" strand="+" transcript="NM_006015">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3071" cds-effect="523_524insAAGTGTGACCAGTGTGATTACG" depth="648" equivocal="false" functional-effect="frameshift" gene="CTCF" percent-reads="30.71" position="chr16:67660607" protein-effect="A175fs*3" status="likely" strand="+" transcript="NM_001191022">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4686" cds-effect="224C&gt;G" depth="414" equivocal="false" functional-effect="missense" gene="C17orf39" percent-reads="46.86" position="chr17:17943002" protein-effect="P75R" status="unknown" strand="+" transcript="NM_024052">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4841" cds-effect="155C&gt;T" depth="659" equivocal="false" functional-effect="missense" gene="RAD51D" percent-reads="48.41" position="chr17:33444046" protein-effect="A52V" status="unknown" strand="-" transcript="NM_001142571">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3077" cds-effect="221G&gt;T" depth="546" equivocal="false" functional-effect="missense" gene="GATA3" percent-reads="30.77" position="chr10:8097839" protein-effect="R74M" status="unknown" strand="+" transcript="NM_001002295">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4417" cds-effect="3982G&gt;A" depth="840" equivocal="false" functional-effect="missense" gene="IGF1R" percent-reads="44.17" position="chr15:99500549" protein-effect="G1328S" status="unknown" strand="+" transcript="NM_000875">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3519" cds-effect="1052C&gt;A" depth="756" equivocal="false" functional-effect="missense" gene="NTRK1" percent-reads="35.19" position="chr1:156843626" protein-effect="P351H" status="unknown" strand="+" transcript="NM_002529">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3694" cds-effect="389G&gt;C" depth="953" equivocal="false" functional-effect="missense" gene="PTEN" percent-reads="36.94" position="chr10:89692905" protein-effect="R130P" status="known" strand="+" transcript="NM_000314">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.2746" cds-effect="1112G&gt;T" depth="641" equivocal="false" functional-effect="missense" gene="ARAF" percent-reads="27.46" position="chrX:47428152" protein-effect="G371V" status="unknown" strand="+" transcript="NM_001654">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.2823" cds-effect="1789_1796delTGGTTGGG" depth="999" equivocal="false" functional-effect="frameshift" gene="PIK3R1" percent-reads="28.23" position="chr5:67591290" protein-effect="W597fs*2" status="likely" strand="+" transcript="NM_181523">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4596" cds-effect="1367G&gt;A" depth="581" equivocal="false" functional-effect="missense" gene="IKBKE" percent-reads="45.96" position="chr1:206653816" protein-effect="R456Q" status="unknown" strand="+" transcript="NM_014002">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.327" cds-effect="781G&gt;T" depth="685" equivocal="false" functional-effect="missense" gene="CTCF" percent-reads="32.7" position="chr16:67645516" protein-effect="G261C" status="unknown" strand="+" transcript="NM_006565">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4691" cds-effect="4793A&gt;T" depth="631" equivocal="false" functional-effect="missense" gene="NOTCH3" percent-reads="46.91" position="chr19:15281580" protein-effect="D1598V" status="unknown" strand="-" transcript="NM_000435">
          <dna-evidence sample="SQ-US1572255.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations />
      <rearrangements />
      <biomarkers>
        <microsatellite-instability status="MSI-H" />
        <tumor-mutation-burden score="14.48" status="intermediate" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content />
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
